UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-Q
(Mark One)
☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended May 1, 2021April 30, 2022
OR
☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission File Number: 001-39878
Petco Health and Wellness Company, Inc.
(Exact Name of Registrant as Specified in its Charter)
Delaware | 81-1005932 |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
|
|
10850 Via Frontera San Diego, California | 92127 |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (858) 453-7845
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
| Trading Symbol(s) |
| Name of each exchange on which registered |
Class A Common Stock, par value $0.001 per share |
| WOOF |
| The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer |
|
|
| Accelerated filer |
| ☐ |
Non-accelerated filer |
|
|
| Smaller reporting company |
| ☐ |
Emerging growth company |
| ☐ |
|
|
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes ☒ No ☐
The number of shares of Registrant’sthe registrant’s Class A Common Stock outstanding as of June 8, 20217, 2022 was 226,479,442.227,628,622 .
The number of shares of Registrant’sthe registrant’s Class B-1 Common Stock outstanding as of June 8, 20217, 2022 was 37,790,781.
The number of shares of Registrant’sthe registrant’s Class B-2 Common Stock outstanding as of June 8, 20217, 2022 was 37,790,781.
Table of Contents
|
| Page |
|
|
|
PART I. |
| |
|
|
|
Item 1. |
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 15 |
Item 3. |
| |
Item 4. |
| |
|
|
|
PART II. | 25 | |
|
|
|
Item 1. | 25 | |
Item 1A. | 25 | |
Item 2. |
| |
Item 3. |
| |
Item 4. |
| |
Item 5. |
| |
Item 6. |
| |
|
Forward-LookingStatements
This Quarterly Report on Form 10-Q (this “Form 10-Q”) contains “forward-looking statements” within the meaning of the PrivateSecurities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, asamended, and Section 21E of the Securities Exchange Act of 1934, as amended, concerningexpectations, beliefs plans, objectives, goals, strategies, future events or performance and underlyingassumptions and other statements that are not statements of historical fact, including statements regarding: our expectations with respect to our revenue, expenses, profitability, and other operating results; our growth plans; our ability to compete effectively in the markets in which we participate; the execution on our transformation initiatives; and the impact of the COVID-19 pandemic on our business.Forward-looking and other statements in this Form 10-Q may also address our progress, plans, and goals with respect to sustainability initiatives, and the inclusion of such statements is not an indication that these contents are necessarily material to investors or required to be disclosed in our filings with the U.S. Securities and Exchange Commission (the “SEC”). Such plans and goals may change, and statements regarding such plans and goals are not guarantees or promises that they will be met. In addition, historical, current, and forward-looking sustainability-related statements may be based on standards for measuring progress that are still developing, internal controls and processes that continue to evolve, and assumptions that are subject to change in the future.
Such forward-looking statements can generally be identified by the use of forward-looking terms such as “believes,” “expects,” “may,” “intends,” “will,” “shall,” “should,” “anticipates,”“opportunity,” “illustrative”, or the negative thereof or other variations thereon or comparableterminology. Although we believe that the expectations and assumptions reflected in these statements are reasonable, there can be no assurance that these expectations will prove to becorrect or that any forward-looking results will occur or be realized. Nothingcontainedin thisForm 10-Qis,orshouldberelieduponas,apromise orrepresentationor warranty as to any future matter, including any matter in respect of our operations or business orfinancial condition. All forward-looking statements are based on expectations and assumptions about futureevents that may or may not be correct or necessarily take place and that are by their nature subject tosignificantuncertaintiesandcontingencies,manyofwhichareoutsideof ourcontrol.
Forward-looking statements are subject to many risks, uncertainties and other factors that could causeactualresults or events todiffermateriallyfromthepotentialresults or events discussedinsuchforward-lookingstatements,including, without limitation, those identified in this Form 10-Q as well as the following: (i) increasedcompetition (including from multi-channel retailers and e-Commerce providers); (ii) reduced consumerdemand for our products and/or services; (iii) our reliance on key vendors; (iv) our ability to attract andretain qualified employees; (v) risks arising from statutory, regulatory and/or legal developments; (vi)macroeconomic pressures in the markets in which we operate, including inflation; (vii) failure to effectively manage ourcosts; (viii) our reliance on our information technology systems; (ix) our ability to prevent or effectivelyrespond to a privacy or security breach; (x) our ability to effectively manage or integrate strategic ventures, alliances or acquisitions and realize the anticipated benefits of such transactions; (xi) economic or regulatory developments that might affect our ability to provideattractive promotional financing; (xii) business interruptions and other supply chain issues; (xiii) catastrophicevents, political tensions, conflicts and wars (such as the ongoing conflict in Ukraine), health crises, and pandemics, including the potential effects that the ongoing COVID-19pandemic and/or corresponding macroeconomic uncertainty could have on our financial position,results of operations and cash flows; (xiv) our ability to maintain positive brand perception andrecognition; (xv) product safety and quality concerns; (xvi) changes to labor or employment laws orregulations; (xvii) our ability to effectively manage our real estate portfolio; (xviii) constraints in thecapital markets or our vendor credit terms; (xix) changes in our credit ratings; and (xx) the other risks, uncertainties and other factors identified under “Risk Factors” and elsewhere in our other filings with the SEC.The occurrence ofany such factors could significantly alter the results set forth in thesestatements.
We caution that the foregoing list of risks, uncertainties and other factors is not complete, and forward-lookingstatements speak only as of the date they are made. We undertake no duty to update publicly any suchforward-looking statement, whether as a result of new information, future events orotherwise,exceptasmay berequiredbyapplicablelaw,regulationorothercompetentlegalauthority.
In addition, statements such as “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this Form 10-Q. While we believe that information provides a reasonable basis for these statements, that information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements.
PART I—FINANCIAL INFORMATION
Item 1. Financial Statements.
PETCO HEALTH AND WELLNESS COMPANY, INC.
CONSOLIDATED BALANCE SHEETS
(In thousands, except per share amounts)
|
| May 1, 2021 |
|
| January 30, 2021 |
|
| April 30, 2022 |
|
| January 29, 2022 |
| ||||
|
| (Unaudited) |
|
|
|
|
|
| (Unaudited) |
|
|
|
|
| ||
ASSETS |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents |
| $ | 174,034 |
|
| $ | 111,402 |
|
| $ | 190,893 |
|
| $ | 211,602 |
|
Receivables, less allowance for credit losses ($2,217 and $3,267, respectively) |
|
| 38,079 |
|
|
| 41,827 |
| ||||||||
Receivables, less allowance for credit losses ($1,114 and $931, respectively) |
|
| 42,221 |
|
|
| 55,618 |
| ||||||||
Merchandise inventories, net |
|
| 574,683 |
|
|
| 538,675 |
|
|
| 682,040 |
|
|
| 675,111 |
|
Prepaid expenses |
|
| 46,724 |
|
|
| 40,032 |
|
|
| 52,129 |
|
|
| 42,355 |
|
Other current assets |
|
| 42,355 |
|
|
| 45,613 |
|
|
| 81,602 |
|
|
| 86,091 |
|
Total current assets |
|
| 875,875 |
|
|
| 777,549 |
|
|
| 1,048,885 |
|
|
| 1,070,777 |
|
Fixed assets |
|
| 1,535,617 |
|
|
| 1,487,987 |
|
|
| 1,792,202 |
|
|
| 1,745,691 |
|
Less accumulated depreciation |
|
| (896,195 | ) |
|
| (860,440 | ) |
|
| (1,056,858 | ) |
|
| (1,018,769 | ) |
Fixed assets, net |
|
| 639,422 |
|
|
| 627,547 |
|
|
| 735,344 |
|
|
| 726,922 |
|
Operating lease right-of-use assets |
|
| 1,330,816 |
|
|
| 1,328,108 |
|
|
| 1,356,879 |
|
|
| 1,338,465 |
|
Goodwill |
|
| 2,179,310 |
|
|
| 2,179,310 |
|
|
| 2,183,991 |
|
|
| 2,183,991 |
|
Trade name |
|
| 1,025,000 |
|
|
| 1,025,000 |
|
|
| 1,025,000 |
|
|
| 1,025,000 |
|
Other intangible assets |
|
| 4,793 |
|
|
| 4,793 |
| ||||||||
Less accumulated amortization |
|
| (4,164 | ) |
|
| (4,079 | ) | ||||||||
Other intangible assets, net |
|
| 629 |
|
|
| 714 |
| ||||||||
Other long-term assets |
|
| 142,347 |
|
|
| 137,474 |
|
|
| 155,688 |
|
|
| 152,786 |
|
Total assets |
| $ | 6,193,399 |
|
| $ | 6,075,702 |
|
| $ | 6,505,787 |
|
| $ | 6,497,941 |
|
LIABILITIES AND EQUITY |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts payable and book overdrafts |
| $ | 352,401 |
|
| $ | 339,485 |
|
| $ | 392,662 |
|
| $ | 403,976 |
|
Accrued salaries and employee benefits |
|
| 127,000 |
|
|
| 129,484 |
|
|
| 125,616 |
|
|
| 150,630 |
|
Accrued expenses and other liabilities |
|
| 218,926 |
|
|
| 145,846 |
|
|
| 213,396 |
|
|
| 210,872 |
|
Current portion of operating lease liabilities |
|
| 276,619 |
|
|
| 258,289 |
|
|
| 258,349 |
|
|
| 265,897 |
|
Current portion of long-term debt and other lease liabilities |
|
| 20,234 |
|
|
| 2,203 |
|
|
| 21,789 |
|
|
| 21,764 |
|
Total current liabilities |
|
| 995,180 |
|
|
| 875,307 |
|
|
| 1,011,812 |
|
|
| 1,053,139 |
|
Senior secured credit facilities, net, excluding current portion |
|
| 1,649,509 |
|
|
| 1,646,281 |
|
|
| 1,637,365 |
|
|
| 1,640,390 |
|
Operating lease liabilities, excluding current portion |
|
| 1,056,059 |
|
|
| 1,083,575 |
|
|
| 1,114,268 |
|
|
| 1,096,133 |
|
Deferred taxes, net |
|
| 282,350 |
|
|
| 280,920 |
|
|
| 322,626 |
|
|
| 318,355 |
|
Other long-term liabilities |
|
| 138,069 |
|
|
| 134,354 |
|
|
| 132,009 |
|
|
| 134,105 |
|
Total liabilities |
|
| 4,121,167 |
|
|
| 4,020,437 |
|
|
| 4,218,080 |
|
|
| 4,242,122 |
|
Commitments and contingencies (Notes 3, 4 and 8) |
|
|
|
|
|
|
|
| ||||||||
Commitments and contingencies (Notes 3 and 6) |
|
|
|
|
|
|
|
| ||||||||
Stockholders' equity: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class A common stock, $0.001 par value: Authorized - 1.0 billion shares; Issued and outstanding - 226.5 million shares as of May 1, 2021 and 226.4 million shares as of January 30, 2021 |
|
| 226 |
|
|
| 226 |
| ||||||||
Class A common stock, $0.001 par value: Authorized - 1.0 billion shares; Issued and outstanding - 227.5 million and 227.2 million shares, respectively |
|
| 227 |
|
|
| 227 |
| ||||||||
Class B-1 common stock, $0.001 par value: Authorized - 75.0 million shares; Issued and outstanding - 37.8 million shares |
|
| 38 |
|
|
| 38 |
|
|
| 38 |
|
|
| 38 |
|
Class B-2 common stock, $0.000001 par value: Authorized - 75.0 million shares; Issued and outstanding - 37.8 million shares |
|
| 0 |
|
|
| 0 |
|
|
| — |
|
|
| — |
|
Preferred stock, $0.001 par value: Authorized - 25.0 million shares; Issued and outstanding - NaN |
|
| 0 |
|
|
| 0 |
|
|
| — |
|
|
| — |
|
Additional paid-in-capital |
|
| 2,103,714 |
|
|
| 2,092,110 |
|
|
| 2,143,505 |
|
|
| 2,133,821 |
|
Accumulated deficit |
|
| (14,691 | ) |
|
| (22,251 | ) | ||||||||
Retained earnings |
|
| 166,859 |
|
|
| 142,166 |
| ||||||||
Accumulated other comprehensive loss |
|
| (2,061 | ) |
|
| (1,275 | ) |
|
| (3,836 | ) |
|
| (2,238 | ) |
Total stockholders’ equity |
|
| 2,087,226 |
|
|
| 2,068,848 |
|
|
| 2,306,793 |
|
|
| 2,274,014 |
|
Noncontrolling interest |
|
| (14,994 | ) |
|
| (13,583 | ) |
|
| (19,086 | ) |
|
| (18,195 | ) |
Total equity |
|
| 2,072,232 |
|
|
| 2,055,265 |
|
|
| 2,287,707 |
|
|
| 2,255,819 |
|
Total liabilities and equity |
| $ | 6,193,399 |
|
| $ | 6,075,702 |
|
| $ | 6,505,787 |
|
| $ | 6,497,941 |
|
See accompanying notes to consolidated financial statements.
PETCO HEALTH AND WELLNESS COMPANY, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts) (Unaudited)
|
| Thirteen weeks ended |
|
| Thirteen weeks ended |
| ||||||||||
|
| May 1, 2021 |
|
| May 2, 2020 |
|
| April 30, 2022 |
|
| May 1, 2021 |
| ||||
Net sales |
| $ | 1,414,994 |
|
| $ | 1,113,521 |
|
| $ | 1,475,991 |
|
| $ | 1,414,994 |
|
Cost of sales |
|
| 818,009 |
|
|
| 647,239 |
|
|
| 868,317 |
|
|
| 818,009 |
|
Gross profit |
|
| 596,985 |
|
|
| 466,282 |
|
|
| 607,674 |
|
|
| 596,985 |
|
Selling, general and administrative expenses |
|
| 549,236 |
|
|
| 449,917 |
|
|
| 557,735 |
|
|
| 549,236 |
|
Operating income |
|
| 47,749 |
|
|
| 16,365 |
|
|
| 49,939 |
|
|
| 47,749 |
|
Interest income |
|
| (21 | ) |
|
| (184 | ) |
|
| (20 | ) |
|
| (21 | ) |
Interest expense |
|
| 20,529 |
|
|
| 60,808 |
|
|
| 19,634 |
|
|
| 20,529 |
|
Loss on extinguishment and modification of debt |
|
| 20,838 |
|
|
| 0 |
|
|
| 0 |
|
|
| 20,838 |
|
Income (loss) before income taxes and income from equity method investees |
|
| 6,403 |
|
|
| (44,259 | ) | ||||||||
Income tax expense (benefit) |
|
| 2,679 |
|
|
| (10,555 | ) | ||||||||
Other non-operating income |
|
| (314 | ) |
|
| 0 |
| ||||||||
Income before income taxes and income from equity method investees |
|
| 30,639 |
|
|
| 6,403 |
| ||||||||
Income tax expense |
|
| 10,000 |
|
|
| 2,679 |
| ||||||||
Income from equity method investees |
|
| (2,425 | ) |
|
| (332 | ) |
|
| (3,163 | ) |
|
| (2,425 | ) |
Net income (loss) |
|
| 6,149 |
|
|
| (33,372 | ) | ||||||||
Net income |
|
| 23,802 |
|
|
| 6,149 |
| ||||||||
Net loss attributable to noncontrolling interest |
|
| (1,411 | ) |
|
| (2,204 | ) |
|
| (891 | ) |
|
| (1,411 | ) |
Net income (loss) attributable to Class A and B-1 common stockholders |
| $ | 7,560 |
|
| $ | (31,168 | ) | ||||||||
Net income attributable to Class A and B-1 common stockholders |
| $ | 24,693 |
|
| $ | 7,560 |
| ||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) per Class A and B-1 common share (1): |
|
|
|
|
|
|
|
| ||||||||
Net income per Class A and B-1 common share: |
|
|
|
|
|
|
|
| ||||||||
Basic |
| $ | 0.03 |
|
| $ | (0.15 | ) |
| $ | 0.09 |
|
| $ | 0.03 |
|
Diluted |
| $ | 0.03 |
|
| $ | (0.15 | ) |
| $ | 0.09 |
|
| $ | 0.03 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares used in computing net income (loss) per Class A and B-1 common share (1): |
|
|
|
|
|
|
|
| ||||||||
Weighted average shares used in computing net income per Class A and B-1 common share: |
|
|
|
|
|
|
|
| ||||||||
Basic |
|
| 264,215 |
|
|
| 209,015 |
|
|
| 265,050 |
|
|
| 264,215 |
|
Diluted |
|
| 265,028 |
|
|
| 209,015 |
|
|
| 265,701 |
|
|
| 265,028 |
|
|
|
See accompanying notes to consolidated financial statements.
PETCO HEALTH AND WELLNESS COMPANY, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(In thousands) (Unaudited)
|
| Thirteen weeks ended |
| |||||
|
| May 1, 2021 |
|
| May 2, 2020 |
| ||
Net income (loss) |
| $ | 6,149 |
|
| $ | (33,372 | ) |
Net loss attributable to noncontrolling interest |
|
| (1,411 | ) |
|
| (2,204 | ) |
Net income (loss) attributable to Class A and B-1 common stockholders |
|
| 7,560 |
|
|
| (31,168 | ) |
|
|
|
|
|
|
|
|
|
Other comprehensive loss, net of tax: |
|
|
|
|
|
|
|
|
Foreign currency translation adjustment |
|
| (786 | ) |
|
| (4,970 | ) |
Unrealized loss on derivatives |
|
| 0 |
|
|
| (52 | ) |
Losses on derivatives reclassified to income |
|
| 0 |
|
|
| 1,728 |
|
Total other comprehensive loss, net of tax |
|
| (786 | ) |
|
| (3,294 | ) |
|
|
|
|
|
|
|
|
|
Comprehensive income (loss) |
|
| 5,363 |
|
|
| (36,666 | ) |
Comprehensive loss attributable to noncontrolling interest |
|
| (1,411 | ) |
|
| (2,204 | ) |
Comprehensive income (loss) attributable to Class A and B-1 common stockholders |
| $ | 6,774 |
|
| $ | (34,462 | ) |
|
| Thirteen weeks ended |
| |||||
|
| April 30, 2022 |
|
| May 1, 2021 |
| ||
Net income |
| $ | 23,802 |
|
| $ | 6,149 |
|
Net loss attributable to noncontrolling interest |
|
| (891 | ) |
|
| (1,411 | ) |
Net income attributable to Class A and B-1 common stockholders |
|
| 24,693 |
|
|
| 7,560 |
|
|
|
|
|
|
|
|
|
|
Other comprehensive loss, net of tax: |
|
|
|
|
|
|
|
|
Foreign currency translation adjustment |
|
| (1,598 | ) |
|
| (786 | ) |
Total other comprehensive loss, net of tax |
|
| (1,598 | ) |
|
| (786 | ) |
|
|
|
|
|
|
|
|
|
Comprehensive income |
|
| 22,204 |
|
|
| 5,363 |
|
Comprehensive loss attributable to noncontrolling interest |
|
| (891 | ) |
|
| (1,411 | ) |
Comprehensive income attributable to Class A and B-1 common stockholders |
| $ | 23,095 |
|
| $ | 6,774 |
|
See accompanying notes to consolidated financial statements.
PETCO HEALTH AND WELLNESS COMPANY, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ / MEMBERS’ EQUITY
(In thousands) (Unaudited)
|
|
|
|
|
| Common stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
|
| Members’ interest (1) |
|
| Class A (shares) |
|
| Class B-1 (shares) |
|
| Class B-2 (shares) |
|
| Amount |
|
| Additional paid-in capital |
|
| Accumulated deficit (1) |
|
| Accumulated other comprehensive loss |
|
| Total stockholders’ equity |
|
| Noncontrolling interest |
|
| Total equity |
| |||||||||||
Balance at January 30, 2021 |
| $ | — |
|
|
| 226,424 |
|
|
| 37,791 |
|
|
| 37,791 |
|
| $ | 264 |
|
| $ | 2,092,110 |
|
| $ | (22,251 | ) |
| $ | (1,275 | ) |
| $ | 2,068,848 |
|
| $ | (13,583 | ) |
| $ | 2,055,265 |
|
Equity-based compensation expense (Note 7) |
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| 11,604 |
|
|
| — |
|
|
| — |
|
|
| 11,604 |
|
|
| — |
|
|
| 11,604 |
|
Net income |
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| 7,560 |
|
|
| — |
|
|
| 7,560 |
|
|
| (1,411 | ) |
|
| 6,149 |
|
Foreign currency translation adjustment, net of tax |
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| (786 | ) |
|
| (786 | ) |
|
| — |
|
|
| (786 | ) |
Issuance of restricted stock awards |
|
| — |
|
|
| 55 |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
Balance at May 1, 2021 |
| $ | — |
|
|
| 226,479 |
|
|
| 37,791 |
|
|
| 37,791 |
|
| $ | 264 |
|
| $ | 2,103,714 |
|
| $ | (14,691 | ) |
| $ | (2,061 | ) |
| $ | 2,087,226 |
|
| $ | (14,994 | ) |
| $ | 2,072,232 |
|
|
| Common stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
|
| Class A (shares) |
|
| Class B-1 (shares) |
|
| Class B-2 (shares) |
|
| Amount |
|
| Additional paid-in capital |
|
| Retained earnings |
|
| Accumulated other comprehensive loss |
|
| Total stockholders’ equity |
|
| Noncontrolling interest |
|
| Total equity |
| ||||||||||
Balance at January 29, 2022 |
|
| 227,187 |
|
|
| 37,791 |
|
|
| 37,791 |
|
| $ | 265 |
|
| $ | 2,133,821 |
|
| $ | 142,166 |
|
| $ | (2,238 | ) |
| $ | 2,274,014 |
|
| $ | (18,195 | ) |
| $ | 2,255,819 |
|
Equity-based compensation expense (Note 5) |
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| 12,055 |
|
|
| — |
|
|
| — |
|
|
| 12,055 |
|
|
| — |
|
|
| 12,055 |
|
Net income |
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| 24,693 |
|
|
| — |
|
|
| 24,693 |
|
|
| (891 | ) |
|
| 23,802 |
|
Foreign currency translation adjustment, net of tax |
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| (1,598 | ) |
|
| (1,598 | ) |
|
| — |
|
|
| (1,598 | ) |
Issuance of common stock, net of tax withholdings |
|
| 291 |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| (2,371 | ) |
|
| — |
|
|
| — |
|
|
| (2,371 | ) |
|
| — |
|
|
| (2,371 | ) |
Balance at April 30, 2022 |
|
| 227,478 |
|
|
| 37,791 |
|
|
| 37,791 |
|
| $ | 265 |
|
| $ | 2,143,505 |
|
| $ | 166,859 |
|
| $ | (3,836 | ) |
| $ | 2,306,793 |
|
| $ | (19,086 | ) |
| $ | 2,287,707 |
|
|
|
|
|
|
| Common stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
|
| Members’ interest (1) |
|
| Class A (shares) |
|
| Class B-1 (shares) |
|
| Class B-2 (shares) |
|
| Amount |
|
| Additional paid-in capital |
|
| Accumulated deficit (1) |
|
| Accumulated other comprehensive loss |
|
| Total members’ equity |
|
| Noncontrolling interest |
|
| Total equity |
| |||||||||||
Balance at February 1, 2020 |
| $ | 1,358,130 |
|
|
| — |
|
|
| — |
|
|
| — |
|
| $ | — |
|
| $ | — |
|
| $ | (780,466 | ) |
| $ | (8,273 | ) |
| $ | 569,391 |
|
| $ | (8,330 | ) |
| $ | 561,061 |
|
Equity-based compensation expense (Note 7) |
|
| 2,305 |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| 2,305 |
|
|
| — |
|
|
| 2,305 |
|
Net loss |
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| (31,168 | ) |
|
| — |
|
|
| (31,168 | ) |
|
| (2,204 | ) |
|
| (33,372 | ) |
Foreign currency translation adjustment, net of tax |
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| (4,970 | ) |
|
| (4,970 | ) |
|
| — |
|
|
| (4,970 | ) |
Unrealized loss on derivatives, net of tax |
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| (52 | ) |
|
| (52 | ) |
|
| — |
|
|
| (52 | ) |
Losses on derivatives reclassified to income, net of tax |
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| 1,728 |
|
|
| 1,728 |
|
|
| — |
|
|
| 1,728 |
|
Balance at May 2, 2020 |
| $ | 1,360,435 |
|
|
| — |
|
|
| — |
|
|
| — |
|
| $ | — |
|
| $ | — |
|
| $ | (811,634 | ) |
| $ | (11,567 | ) |
| $ | 537,234 |
|
| $ | (10,534 | ) |
| $ | 526,700 |
|
|
| Common stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
|
| Class A (shares) |
|
| Class B-1 (shares) |
|
| Class B-2 (shares) |
|
| Amount |
|
| Additional paid-in capital |
|
| Accumulated deficit |
|
| Accumulated other comprehensive loss |
|
| Total stockholders’ equity |
|
| Noncontrolling interest |
|
| Total equity |
| ||||||||||
Balance at January 30, 2021 |
|
| 226,424 |
|
|
| 37,791 |
|
|
| 37,791 |
|
| $ | 264 |
|
| $ | 2,092,110 |
|
| $ | (22,251 | ) |
| $ | (1,275 | ) |
| $ | 2,068,848 |
|
| $ | (13,583 | ) |
| $ | 2,055,265 |
|
Equity-based compensation expense (Note 5) |
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| 11,604 |
|
|
| — |
|
|
| — |
|
|
| 11,604 |
|
|
| — |
|
|
| 11,604 |
|
Net income |
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| 7,560 |
|
|
| — |
|
|
| 7,560 |
|
|
| (1,411 | ) |
|
| 6,149 |
|
Foreign currency translation adjustment, net of tax |
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| (786 | ) |
|
| (786 | ) |
|
| — |
|
|
| (786 | ) |
Issuance of restricted stock awards |
|
| 55 |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
Balance at May 1, 2021 |
|
| 226,479 |
|
|
| 37,791 |
|
|
| 37,791 |
|
| $ | 264 |
|
| $ | 2,103,714 |
|
| $ | (14,691 | ) |
| $ | (2,061 | ) |
| $ | 2,087,226 |
|
| $ | (14,994 | ) |
| $ | 2,072,232 |
|
|
|
See accompanying notes to consolidated financial statements.
PETCO HEALTH AND WELLNESS COMPANY, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands) (Unaudited)
|
| Thirteen weeks ended |
|
| Thirteen weeks ended |
| ||||||||||
|
| May 1, 2021 |
|
| May 2, 2020 |
|
| April 30, 2022 |
|
| May 1, 2021 |
| ||||
Cash flows from operating activities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) |
| $ | 6,149 |
|
| $ | (33,372 | ) | ||||||||
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: |
|
|
|
|
|
|
|
| ||||||||
Net income |
| $ | 23,802 |
|
| $ | 6,149 |
| ||||||||
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
|
|
|
|
| ||||||||
Depreciation and amortization |
|
| 41,607 |
|
|
| 43,567 |
|
|
| 46,967 |
|
|
| 41,607 |
|
Amortization of debt discounts and issuance costs |
|
| 2,165 |
|
|
| 6,028 |
|
|
| 1,224 |
|
|
| 2,165 |
|
Provision for deferred taxes |
|
| 1,708 |
|
|
| (11,680 | ) |
|
| 4,832 |
|
|
| 1,708 |
|
Equity-based compensation |
|
| 11,604 |
|
|
| 2,305 |
|
|
| 12,222 |
|
|
| 11,604 |
|
Impairments, write-offs and losses on sale of fixed and other assets |
|
| 947 |
|
|
| 3,409 |
|
|
| 162 |
|
|
| 947 |
|
Loss on extinguishment and modification of debt |
|
| 20,838 |
|
|
| 0 |
|
|
| 0 |
|
|
| 20,838 |
|
Income from equity method investees |
|
| (2,425 | ) |
|
| (332 | ) |
|
| (3,163 | ) |
|
| (2,425 | ) |
Amounts reclassified out of accumulated other comprehensive income (Note 5) |
|
| 0 |
|
|
| 2,337 |
| ||||||||
Change in contingent consideration obligation |
|
| 0 |
|
|
| (553 | ) | ||||||||
Non-cash operating lease costs |
|
| 105,188 |
|
|
| 108,841 |
|
|
| 105,249 |
|
|
| 105,188 |
|
Other non-operating income |
|
| (314 | ) |
|
| 0 |
| ||||||||
Changes in assets and liabilities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Receivables |
|
| 3,748 |
|
|
| (3,767 | ) |
|
| 13,397 |
|
|
| 3,748 |
|
Merchandise inventories |
|
| (36,008 | ) |
|
| (3,307 | ) |
|
| (6,930 | ) |
|
| (36,008 | ) |
Prepaid expenses and other assets |
|
| (9,140 | ) |
|
| (6,302 | ) |
|
| (9,896 | ) |
|
| (9,140 | ) |
Accounts payable and book overdrafts |
|
| 20,119 |
|
|
| (74,074 | ) |
|
| (11,314 | ) |
|
| 20,119 |
|
Accrued salaries and employee benefits |
|
| (2,483 | ) |
|
| (10,153 | ) |
|
| (16,478 | ) |
|
| (2,483 | ) |
Accrued expenses and other liabilities |
|
| 66,120 |
|
|
| 5,853 |
|
|
| 11,290 |
|
|
| 66,120 |
|
Operating lease liabilities |
|
| (116,994 | ) |
|
| (64,188 | ) |
|
| (112,272 | ) |
|
| (116,994 | ) |
Other long-term liabilities |
|
| 1,859 |
|
|
| 3,099 |
|
|
| (1,259 | ) |
|
| 1,859 |
|
Net cash provided by (used in) operating activities |
|
| 115,002 |
|
|
| (32,289 | ) | ||||||||
Net cash provided by operating activities |
|
| 57,519 |
|
|
| 115,002 |
| ||||||||
Cash flows from investing activities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash paid for fixed assets |
|
| (47,351 | ) |
|
| (27,895 | ) |
|
| (65,910 | ) |
|
| (47,351 | ) |
Net cash used in investing activities |
|
| (47,351 | ) |
|
| (27,895 | ) |
|
| (65,910 | ) |
|
| (47,351 | ) |
Cash flows from financing activities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Borrowings under long-term debt agreements |
|
| 1,700,000 |
|
|
| 397,000 |
|
|
| 0 |
|
|
| 1,700,000 |
|
Repayments of long-term debt |
|
| (1,678,111 | ) |
|
| (142,313 | ) |
|
| (4,250 | ) |
|
| (1,678,111 | ) |
Debt refinancing costs |
|
| (24,665 | ) |
|
| 0 |
|
|
| 0 |
|
|
| (24,665 | ) |
Payments for finance lease liabilities |
|
| (593 | ) |
|
| (935 | ) |
|
| (1,022 | ) |
|
| (593 | ) |
Proceeds from employee stock purchase plan and stock option exercises |
|
| 1,453 |
|
|
| 0 |
| ||||||||
Tax withholdings on stock-based awards |
|
| (11,441 | ) |
|
| 0 |
| ||||||||
Payment of offering costs |
|
| (3,844 | ) |
|
| 0 |
|
|
| 0 |
|
|
| (3,844 | ) |
Net cash (used in) provided by financing activities |
|
| (7,213 | ) |
|
| 253,752 |
| ||||||||
Net increase in cash, cash equivalents and restricted cash |
|
| 60,438 |
|
|
| 193,568 |
| ||||||||
Net cash used in financing activities |
|
| (15,260 | ) |
|
| (7,213 | ) | ||||||||
Net (decrease) increase in cash, cash equivalents and restricted cash |
|
| (23,651 | ) |
|
| 60,438 |
| ||||||||
Cash, cash equivalents and restricted cash at beginning of year |
|
| 119,540 |
|
|
| 154,718 |
|
|
| 221,890 |
|
|
| 119,540 |
|
Cash, cash equivalents and restricted cash at end of year |
| $ | 179,978 |
|
| $ | 348,286 |
|
| $ | 198,239 |
|
| $ | 179,978 |
|
Supplemental cash flow disclosures: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest paid, net |
| $ | 6,958 |
|
| $ | 49,527 |
|
| $ | 17,203 |
|
| $ | 6,958 |
|
Capitalized interest |
| $ | 47 |
|
| $ | 56 |
|
| $ | 55 |
|
| $ | 47 |
|
Income taxes paid |
| $ | 218 |
|
| $ | 288 |
|
| $ | 669 |
|
| $ | 218 |
|
Supplemental non-cash investing and financing activities disclosure: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts payable and accrued expenses for capital expenditures |
| $ | 23,386 |
|
| $ | 15,946 |
|
| $ | 27,083 |
|
| $ | 23,386 |
|
See accompanying notes to consolidated financial statements.
PETCO HEALTH AND WELLNESS COMPANY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
1. Summary of Significant Accounting Policies
Basis of Presentation
Petco Health and Wellness Company, Inc. (together with its consolidated subsidiaries, the “Company”) is a national specialty retailercategory-defining health and wellness company focused on improving the lives of premiumpets, pet consumables, suppliesparents, and companion animals and services.its own partners. The Company manages its business as 1 reportable operating segment.
In the opinion of management, the accompanying condensed consolidated financial statements contain all adjustments necessary for a fair presentation as prescribed by accounting principles generally accepted in the United States (“GAAP”). All adjustments were comprised of normal recurring adjustments, except as noted in these Notes to Consolidated Financial Statements.
There have been no significant changes from the significant accounting policies disclosed in Note 1 of the Notes to Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended January 30, 202129, 2022.
The resultsaccompanying consolidated financial statements have been prepared in accordance with GAAP for interim financial information and the instructions to Form 10-Q and Article 10 of operationsRegulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for the thirteen weeks ended May 1, 2021complete financial statements. Interim financial results are not necessarily indicative of results anticipated for the full year. The accompanying consolidated financial statements and these Notes to Consolidated Financial Statements should be read in conjunction with the audited consolidated financial statements and Notes to Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended January 29, 2022, from which the prior year balance sheet information herein was derived.
Veterinary Joint Venture
As of April 30, 2022, the Company held a 50% investment in a joint venture with a domestic partner to build and operate veterinary clinics in Petco locations. The joint venture was a variable interest entity for which the Company was the primary beneficiary, and accordingly, the joint venture’s results of operations that may be achieved for the entire fiscal year ending January 29, 2022.
Corporate Conversion and Initial Public Offering
The Company previously operated as a Delaware limited liability company under the name PET Acquisition LLC. In January 2021, the Company converted to a Delaware corporation pursuant to a statutory conversion and changed its name to Petco Health and Wellness Company, Inc. The existing balancesstatements of members’ interest and accumulated deficit prior to this conversion were reclassified to additional paid-in capitalfinancial position are included in the condensedCompany’s consolidated balance sheets. This reclassification had no effect on the Company’s results of operations.
On January 19, 2021,financial statements. In May 2022, the Company completed its initial public offering of 55.2 million newly-issued shares of its Class A common stock. The offering price was $18.00 per share. The net proceeds from the initial public offering were used to pay a portionpurchase of the principal amountremaining 50% of the issued and accrued interest onoutstanding membership interests of the Company’s debt obligations. Refer to Note 3 and Note 4 for further discussion on the Company’s usejoint venture, which is now a wholly owned subsidiary of proceeds from the initial public offering.
Subsequent Event
On June 1, 2021, Scooby Aggregator, LP, the Company’s principal stockholder, completed the sale of 22 million existing shares of Class A common stock in connection with a secondary offering. The offering price to the public was $24.00 per share. The Company received 0 proceeds from the secondary offering. Expenses incurred by the Company, for cash consideration of $35.0 million. Direct transaction costs related to the secondary offeringthis purchase were not material.
Use of Estimates
The preparation of these condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. These estimates are based on information that is currently available and on various other assumptions that are believed to be reasonable under the circumstances. Actual results could vary from those estimates under different assumptions or conditions.
Cash and Cash Equivalents
The following table provides a reconciliation of cash, cash equivalents and restricted cash reported in the condensed consolidated balance sheets to the total amounts reported in the condensed consolidated statements of cash flows.flows (in thousands).
|
| May 1, 2021 |
|
| January 30, 2021 |
|
| April 30, 2022 |
|
| January 29, 2022 |
| ||||
Cash and cash equivalents |
| $ | 174,034 |
|
| $ | 111,402 |
|
| $ | 190,893 |
|
| $ | 211,602 |
|
Restricted cash included in other current assets |
|
| 5,944 |
|
|
| 8,138 |
|
|
| 7,346 |
|
|
| 10,288 |
|
Total cash, cash equivalents and restricted cash in the statement of cash flows |
| $ | 179,978 |
|
| $ | 119,540 |
|
| $ | 198,239 |
|
| $ | 221,890 |
|
Recent Accounting Pronouncements
In June 2016,March 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2016-132020-04 – Financial Instruments – Credit LossesReference Rate Reform (Topic 326)848): MeasurementFacilitation of Credit Lossesthe Effects of Reference Rate Reform on Financial Instruments,Reporting, which amendsprovides optional expedients and exceptions for applying GAAP to contract modifications, hedging relationships, and other transactions affected by the accountinganticipated transition from LIBOR. As a result of the reference rate reform initiative, certain widely used reference rates such as LIBOR are expected to be discontinued. The guidance is designed to simplify how entities account for recognizing impairments of financial assets. Under thecontracts, such as receivables, debt, leases, derivative instruments and hedging, that are modified to replace LIBOR or other benchmark interest rates with new accountingrates. The guidance credit losses for financial assets held at amortized cost willis effective upon issuance and may be estimated based on expected losses rather than the current incurred loss impairment model. The new accounting guidance also modifies the impairment model for available-for-sale debt securities.applied through December 31, 2022. The Company adoptedis currently evaluating the impact of this accounting policy on February 2, 2020. The adoption didstandard, but does not expect it to have a material impact on the Company’s condensed consolidated financial statements and related disclosures.
In August 2018, FASB issued Accounting Standards Update No. 2018-15 – Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40), which amends ASC 350-40 to address a customer’s accounting for implementation costs incurred in a cloud computing arrangement that is a service contract. The Company adopted this accounting policy on February 2, 2020. The adoption did not have a material impact on the Company’s condensed consolidated financial statements and related disclosures.
2. Revenue Recognition
Net sales by product type and services were as follows (in thousands):
| Thirteen weeks ended |
| Thirteen weeks ended |
| ||||||||||
| May 1, 2021 |
|
| May 2, 2020 |
| April 30, 2022 |
|
| May 1, 2021 |
| ||||
Dog and cat food | $ | 595,132 |
|
| $ | 525,752 |
| |||||||
Consumables | $ | 685,930 |
|
| $ | 595,132 |
| |||||||
Supplies and companion animals |
| 658,172 |
|
|
| 493,734 |
|
| 599,179 |
|
|
| 658,172 |
|
Services and other |
| 161,690 |
|
|
| 94,035 |
|
| 190,882 |
|
|
| 161,690 |
|
Net sales | $ | 1,414,994 |
|
| $ | 1,113,521 |
| $ | 1,475,991 |
|
| $ | 1,414,994 |
|
3. Senior Secured Credit Facilities
As of January 30, 2021, theThe Company previously had a senior secured term loan facility (the “Amended Term Loan Facility”), which was fully repaid on March 4, 2021, and a senior secured asset-based revolving credit facility (the “Amended Revolving Credit Facility”), which was terminated on March 4, 2021. On March 4, 2021, the Company entered into a $1,700.0 million secured term loan facility maturing on March 4, 2028 (the “First Lien Term Loan”) and a secured asset-based revolving credit facility with availability of up to $500.0 million, subject to a borrowing base, maturing on March 4, 2026 (the “ABL Revolving Credit Facility”). The Amended Term Loan Facility, the Amended Revolving Credit Facility, the First Lien Term Loan, and the ABL Revolving Credit Facility are collectively referred to as the “Senior Secured Credit Facilities.”
As of May 1, 2021,April 30, 2022, the Company was in compliance with its covenants inunder the First Lien Term Loan and the ABL Revolving Credit Facility.
Term Loan Facilities
On January 19, 2021, the Company repaid $727.0 million of the Amended Term Loan Facility using a portion of the proceeds from its initial public offering, in addition to existing cash on hand. The repayment was applied to the remaining principal payments in order of scheduled payment date and, as a result, no quarterly principal payments remained under the Amended Term Loan Facility, other than the remaining principal balance due at maturity. As such, the entire remaining balance was included in senior secured credit facilities, net, excluding current portion in the condensed consolidated balance sheets as of January 30, 2021.
On March 4, 2021, the Company entered into the $1,700.0 million First Lien Term Loan and repaid all outstanding principal and interest on the Amended Term Loan Facility. Interest underon the First Lien Term Loan is based on, at the Company’s option, either a base rate or Adjusted LIBOR, subject to a 0.75% floor, payable upon maturity of the LIBOR contract, in either case, plus the applicable rate. The base rate is the greater of the bank prime rate, federal
funds effective rate plus 0.5% or Adjusted LIBOR plus 1.0%. The applicable rate is 2.25% per annum for a base rate loan or 3.25% per annum for an Adjusted LIBOR loan. Principal and interest payments commencecommenced on June 30, 2021. Principal payments are $4.25 million quarterly.
In connection with the March 4, 2021 transaction described above, the Company recognized a loss on debt extinguishment and modification of $19.6 million on the term loan facilities, which consisted of a $6.5 million write-off of unamortized debt discount and issuance costs on the Amended Term Loan Facility and $13.1 million of third-party expenses.
Fees relating to the Company’s entry into the First Lien Term Loan consisted of arranger fees and other third-party expenses. Of those fees, $3.2 million was capitalized as debt issuance costs, along with $4.3 million of original issue discount. The remaining portion of original issue discount and debt issuance costs of the Amended Term Loan Facility previously capitalized is being amortized over the contractual term of the First Lien Term Loan to interest expense using the effective interest rate in effect on the date of issuance, as these amounts represent the portion that was not substantially modified.
As of May 1, 2021,April 30, 2022, the outstanding principal balance of the First Lien Term Loan was $1,700.0$1,683.0 million ($1,672.11,658.8 million, net of the unamortized discount and debt issuance costs). As of January 30, 2021,29, 2022, the outstanding principal balance of the AmendedFirst Lien Term Loan Facility was $1,678.1$1,687.3 million ($1,649.41,662.1 million, net of the unamortized discount and debt issuance costs). The weighted average interest rate on the borrowings outstanding was 4.1%4.3% and 4.3%4.1% as of May 1, 2021April 30, 2022 and January 30, 2021,29, 2022, respectively. Debt issuance costs are being amortized over the contractual term to interest expense using the effective interest rate in effect at issuance. As of May 1, 2021,April 30, 2022 and January 29, 2022, the estimated fair value of the First Lien Term Loan was approximately $1,689.4$1,662.0 million based upon Level 2 fair value hierarchy inputs. As of January 30, 2021, the estimated fair value of the Amended Term Loan Facility was approximately $1,673.9and $1,687.3 million, respectively, based upon Level 2 fair value hierarchy inputs.
Revolving Credit Facilities
On March 4, 2021, the Company entered into an agreement establishing the ABL Revolving Credit Facility and terminated the Amended Revolving Credit Facility. The ABL Revolving Credit Facility has availability up to $500.0 million, subject to a borrowing base.
Fees relating to the Company’s entry into the ABL Revolving Credit Facility consisted of arranger fees and other third-party expenses. Of those fees, $4.1 million was capitalized as debt issuance costs. Unamortized debt issuance costs of $1.2 million were written off and recognized as a loss on debt extinguishment and modification in connection with this transaction. The remaining portion of debt issuance costs of the Amended Revolving Credit Facility previously capitalized is being amortized over the contractual term of the ABL Revolving Credit Facility as these amounts represent the portion that was not substantially modified.
As of May 1, 2021,April 30, 2022 and January 29, 2022, 0 amounts were outstanding under the ABL Revolving Credit Facility. As of JanuaryAt April 30, 2021, 0 amounts were outstanding under the Amended Revolving Credit Facility. At May 1, 2021, $420.52022, $438.8 million was available under the ABL Revolving Credit Facility, which is net of $56.6$61.2 million of outstanding letters of credit issued in the normal course of business and a $22.9 million0 borrowing base reduction for a shortfall in qualifying
assets, net of reserves. assets. Unamortized debt issuance costs of $5.6$4.5 million relating to the ABL Revolving Credit Facility were outstanding and were being amortized using the straight-line method over the remaining term of the agreement as of May 1, 2021.April 30, 2022. Unamortized debt issuance costs of $3.1$4.7 million relating to the AmendedABL Revolving Credit Facility were outstanding and were being amortized using the straight-line method over the remaining term of the agreement as of January 30, 2021.29, 2022.
The ABL Revolving Credit Facility has availability up to $500.0 million and a $150.0 million letter of credit sub-facility. The availability is limited to a borrowing base, which allows borrowings of up to 90% of eligible accounts receivable plus 90% of the net orderly liquidation value of eligible inventory plus up to $50$50.0 million of qualified cash of the Company to which the Company and guarantors have no access, less reserves as determined by the administrative agent. Letters of credit reduce the amount available to borrow under the ABL Revolving Credit Facility by their face value.
Interest on the ABL Revolving Credit Facility is based on, at the Company’s option, either the base rate or Adjusted LIBOR subject to a floor of 0%, in either case, plus an applicable margin. The applicable margin is currently equal to 25 basis points in the case of base rate loans and 125 basis points in the case of Adjusted LIBOR loans.
The applicable margin is adjusted quarterly based on the average historical excess availability as a percentage of the Line Cap, which represents the lesser of the aggregate ABL Revolving Credit Facility and the borrowing base, as follows:
Average Historical Excess Availability |
| Applicable Margin for Adjusted LIBOR Loans |
|
| Applicable Margin for Base Rate Loans |
| ||
Less than 33.3% of the Line Cap |
|
| 1.75 | % |
|
| 0.75 | % |
Less than 66.7% but greater than or equal to 33.3% of the Line Cap |
|
| 1.50 | % |
|
| 0.50 | % |
Greater than or equal to 66.7% of the Line Cap |
|
| 1.25 | % |
|
| 0.25 | % |
The ABL Revolving Credit Facility is subject to an unused commitment fee. If the actual daily utilized portion exceeds 50%, the unused commitment fee is 0.25%. Otherwise, the unused commitment fee is 0.375% and is not dependent upon excess availability.
4. Senior Notes
Floating Rate Senior Notes
On January 26, 2016, the Company issued $750.0 million of unsecured senior notes maturing on January 26, 2024 in a private offering (the “Floating Rate Senior Notes”). Debt issuance costs of $26.2 million related to the Floating Rate Senior Notes were being amortized over the contractual term to interest expense using the effective interest rate in effect at issuance. The Floating Rate Senior Notes bore interest at a floating rate equal to three-month LIBOR, subject to a 1.00% floor, plus 8.0% per annum (the “Applicable Margin”) payable quarterly in arrears.
On January 19, 2021, in connection with the Company’s initial public offering, the holders of the outstanding Floating Rate Senior Notes exchanged $450.0 million of the aggregate principal amount of the Floating Rate Senior Notes for a new series of notes with a principal amount of $450.0 million issued by Scooby Aggregator, LP, the Company’s principal stockholder. Scooby Aggregator, LP, as the new holder of $450.0 million of Floating Rate Senior Notes, contributed the principal balance to the Company. This contribution, offset by approximately $7.4 million of unamortized deferred financing costs associated with the principal balance contributed, was recorded as an adjustment to additional paid-in capital.
On January 19, 2021, the Company repaid the remaining $300.0 million principal balance of the Floating Rate Senior Notes using a portion of the proceeds from its initial public offering, in addition to existing cash on hand.
3.00% Senior Notes
On January 26, 2016, the Company issued senior unsecured notes maturing on January 25, 2019 in a private offering to its members. Interest on the notes was originally 0.75% per annum, payable semi-annually either in cash or by means of capitalizing such interest and adding it to the then outstanding principal amount of the notes.
On April 6, 2019, the Company amended the notes to extend their maturity to July 25, 2019. Interest under these notes (the “3.00% Senior Notes”) was 3.00% per annum, payable upon maturity. On July 25, 2019, February 3, 2020, and September 28, 2020, the Company further amended the notes to extend their maturity to January 25, 2020, January 25, 2021, and January 25, 2023, respectively.
On January 19, 2021, in connection with its initial public offering, the Company repaid $4.0 million of the principal balance of the 3.00% Senior Notes. The remaining $127.7 million of principal and $3.6 million of accrued interest was then contributed to the Company.
5. Derivative Instruments
In March 2016, the Company entered into a series of 5 interest rate cap agreements with four counterparties with a total notional value of $1,950.0 million to limit the maximum interest rate on a portion of the Company’s variable-rate debt and limit its exposure to interest rate variability when the three-month LIBOR exceeds 2.25%.
The interest rate caps were accounted for as cash flow hedges because the interest rate caps were expected to be highly effective in hedging variable rate interest payments. Changes in the fair value of the interest rate caps were reported as a component of AOCI. The interest rate caps expired and were settled in accordance with their contractual terms on January 29, 2021.
6. Fair Value Measurements
Assets and Liabilities Measured on a Recurring Basis
The following table presents information about assets and liabilities that are measured at fair value on a recurring basis and indicate the fair value hierarchy of the valuation techniques utilized to determine such fair value (in thousands):
|
| May 1, 2021 |
|
| April 30, 2022 |
| ||||||||||||||||||
|
| Level 1 |
|
| Level 2 |
|
| Level 3 |
|
| Level 1 |
|
| Level 2 |
|
| Level 3 |
| ||||||
Assets (liabilities): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Money market mutual funds |
| $ | 121,405 |
|
| $ | 0 |
|
| $ | 0 |
|
| $ | 143,695 |
|
| $ | 0 |
|
| $ | 0 |
|
Investments of officer’s life insurance |
| $ | 0 |
|
| $ | 15,271 |
|
| $ | 0 |
| ||||||||||||
Investments of officers' life insurance |
| $ | 0 |
|
| $ | 13,080 |
|
| $ | 0 |
| ||||||||||||
Non-qualified deferred compensation plan |
| $ | 0 |
|
| $ | (16,862 | ) |
| $ | 0 |
|
| $ | 0 |
|
| $ | (18,151 | ) |
| $ | 0 |
|
Investment in Rover Group, Inc. |
| $ | 33,133 |
|
| $ | 0 |
|
| $ | 0 |
|
|
| January 30, 2021 |
|
| January 29, 2022 |
| ||||||||||||||||||
|
| Level 1 |
|
| Level 2 |
|
| Level 3 |
|
| Level 1 |
|
| Level 2 |
|
| Level 3 |
| ||||||
Assets (liabilities): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Money market mutual funds |
| $ | 63,798 |
|
| $ | 0 |
|
| $ | 0 |
|
| $ | 167,277 |
|
| $ | 0 |
|
| $ | 0 |
|
Investments of officer’s life insurance |
| $ | 0 |
|
| $ | 14,140 |
|
| $ | 0 |
| ||||||||||||
Investments of officers' life insurance |
| $ | 0 |
|
| $ | 14,575 |
|
| $ | 0 |
| ||||||||||||
Non-qualified deferred compensation plan |
| $ | 0 |
|
| $ | (15,526 | ) |
| $ | 0 |
|
| $ | 0 |
|
| $ | (17,453 | ) |
| $ | 0 |
|
Investment in Rover Group, Inc. |
| $ | 32,819 |
|
| $ | 0 |
|
| $ | 0 |
|
The fair value of money market mutual funds is based on quoted market prices, such as quoted net asset values published by the fund as supported in an active market. Money market mutual funds included in the Company’s cash and cash equivalents were $116.0$137.7 million and $56.0$158.0 million as of May 1, 2021April 30, 2022 and January 30, 2021,29, 2022, respectively. Also included in the Company’s money market mutual funds balances were $5.4$6.0 million and $7.8$9.3 million as of May 1, 2021April 30, 2022 and January 30, 2021,29, 2022, respectively, which relate to the Company’s restricted cash, and are included in other current assets in the condensed consolidated balance sheets.
The Company maintains a deferred compensation plan for key executives and other members of management, which is fully funded by investments in officers’ life insurance. The fair value of this obligation is based on participants’ elected investments, which reflect the closing market prices of similar assets.
The Company previously held an equity investment, in the form of multiple series of preferred stock, in A Place for Rover, Inc., an online marketplace for pet care, which was historically accounted for as an equity security without a readily determinable fair value. In July 2021, A Place for Rover, Inc. completed a business combination with Nebula Caravel Acquisition Corp., a publicly-traded special purpose acquisition company. The combined entity was renamed to Rover Group, Inc. (“Rover”), and the Company’s equity investment was converted into shares of Rover Class A common stock. In September 2021, the Company received additional shares of Rover Class A
common stock in accordance with certain earnout provisions from the July 2021 business combination. The Company now remeasures the fair value of its investment on a quarterly basis, and the resulting gains or losses are included in other non-operating income in the consolidated statements of operations. On November 23, 2021, the Company completed the sale of approximately 11% of its Rover Class A common stock for net proceeds of $6.1 million in cash as part of its participation in an underwritten secondary offering by certain Rover shareholders.
During the thirteen week period ended April 30, 2022, the Company amended a collaboration agreement with a vendor, and as part of the amendment the Company was granted a right to receive equity and warrants for common shares of the vendor that is subject to certain performance conditions and other contingencies. The Company evaluated the agreement under FASB Accounting Standards Codification 705-20, Consideration Received from a Vendor, and 0 consideration was recognized during the thirteen week period ended April 30, 2022.
Assets Measured on a Non-Recurring Basis
The Company’s non-financial assets, which primarily consist of goodwill, other intangible assets, fixed assets and equity and cost methodother investments, are reported at carrying value, or at fair value as of the date of the Company’s acquisition of Petco Holdings, Inc. LLC on January 26, 2016, and are not required to be measured at fair value on a recurring basis. However, on a periodic basis (at least annually for goodwill and indefinite-lived intangibles or whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable), non-financial assets are assessed for impairment. If impaired, the carrying values of the assets are written down to fair value using Level 3 inputs.
There were no triggering events identified and no indication of impairment of the Company’s goodwill, indefinite livedindefinite-lived trade name, other intangible assets or equity and cost methodother investments during the thirteen week periods ended April 30, 2022 and May 1, 2021 and May 2, 2020.2021. During the thirteen week periods ended April 30, 2022 and May 1, 2021, and May 2, 2020, the Company recorded fixed asset and right-of-use asset impairment charges of $1.1$0.9 million and $3.1$1.1 million, respectively.
7.5. Stockholders’ Equity
Equity-Based Compensation
Equity-based compensation awards under the Company’s current incentive plan (the “2021 Equity Incentive Plan”) include restricted stock units (“RSUs”)RSUs,” which include performance-based stock units), restricted stock awards (“RSAs”), non-qualified stock options, and other equity compensation awards. The Company also has an employee stock purchase plan (“ESPP”).
The Company’s controlling parent, Scooby LP, the direct owner of Scooby Aggregator, LP, also maintains an incentive plan (the “2016 Incentive Plan”) under which it has awarded partnership unit awards to employees, consultants, and non-employee directors of the Company.Company that are restricted profit interests in Scooby LP subject to a distribution threshold (“Series C Units”).
The following table summarizes the Company’s equity-based compensation expense by award type (in thousands):
|
| Thirteen weeks ended |
|
| Thirteen weeks ended |
| ||||||||||
|
| May 1, 2021 |
|
| May 2, 2020 |
|
| April 30, 2022 |
|
| May 1, 2021 |
| ||||
RSUs and RSAs |
| $ | 6,471 |
|
| $ | 0 |
|
| $ | 6,466 |
|
| $ | 6,471 |
|
Options |
|
| 2,092 |
|
|
| 0 |
|
|
| 1,808 |
|
|
| 2,092 |
|
ESPP |
|
| 73 |
|
|
| 0 |
|
|
| 297 |
|
|
| 73 |
|
Partnership units of Scooby LP under the 2016 Incentive Plan |
|
| 2,968 |
|
|
| 2,305 |
| ||||||||
Other awards |
|
| 3,651 |
|
|
| 2,968 |
| ||||||||
Total equity-based compensation expense |
| $ | 11,604 |
|
| $ | 2,305 |
|
| $ | 12,222 |
|
| $ | 11,604 |
|
Activity under the 2021 Equity Incentive Plan was as follows (shares and dollars in thousands):
|
| RSUs and RSAs |
|
| Options |
| ||
Nonvested RSUs and RSAs/options outstanding, January 30, 2021 |
|
| 3,414 |
|
|
| 3,482 |
|
Granted |
|
| 130 |
|
|
| 0 |
|
RSUs and RSAs vested/options exercised |
|
| 0 |
|
|
| 0 |
|
Forfeited/expired |
|
| (63 | ) |
|
| (12 | ) |
Nonvested RSUs and RSAs/options outstanding, May 1, 2021 |
|
| 3,481 |
|
|
| 3,470 |
|
Unrecognized compensation expense as of May 1, 2021 |
| $ | 54,714 |
|
| $ | 21,812 |
|
Weighted average remaining expense period as of May 1, 2021 |
| 2.5 years |
|
| 2.7 years |
|
|
| RSUs and RSAs |
|
| Options |
| ||
Nonvested/outstanding, January 29, 2022 |
|
| 2,587 |
|
|
| 3,327 |
|
Granted |
|
| 2,842 |
|
|
| 503 |
|
Vested and delivered/exercised |
|
| (553 | ) |
|
| (44 | ) |
Forfeited/expired |
|
| (117 | ) |
|
| (144 | ) |
Nonvested/outstanding, April 30, 2022 |
|
| 4,759 |
|
|
| 3,642 |
|
Unrecognized compensation expense as of April 30, 2022 |
| $ | 83,537 |
|
| $ | 16,446 |
|
Weighted average remaining expense period as of April 30, 2022 |
| 2.5 years |
|
| 2.1 years |
|
RSA activity has not been material and relates to an RSA of Class A common stock granted to an executive in March 2021. For this grant, 50% of the RSA becomes vested on each of the first two anniversaries of the grant date. Unvested RSAs are not considered participating securities for earnings per share purposes, as any related dividends are forfeitable.
Enrollment in the ESPP began in April 2021. The ESPP will allowallows eligible employees to contribute up to 15% of their base earnings towards purchases of Class A common stock, subject to an annual maximum. The purchase
price will be 85% of the lower of (i) the fair market value of the stock on the associated lookback date and (ii) the fair market value of the stock on the last day of the related purchase period.
Series C Unit activity under the 2016 Incentive Plan was as follows (in thousands):
|
| Units |
| |
Outstanding, January |
|
|
|
|
Granted |
|
| 0 |
|
Forfeited |
|
| ( | ) |
Outstanding, |
|
|
|
|
Vested, |
|
|
| |
|
|
|
NaN additional Series C Units have been or will be awarded following the Company’s initial public offering. As of May 1, 2021,April 30, 2022, unrecognized compensation expense related to the unvested portion of Scooby LP’s Series C Units was $23.8$15.2 million, which is expected to be recognized over a weighted average period of 2.92.0 years. In addition to acceleration upon a change in control, a portion of grantees’ Series C Units may vest upon certain levels of direct or indirect sales by Scooby LP of the Company’s Class A common stock, and all unvested Series C Units will fully accelerate in the event Scooby LP sells 90% of its direct or indirect holdings of the Company’s Class A common stock.
Earnings (Loss) Per Share
Potentially dilutive securities include potential Class A common shares related to outstanding stock options, unvested RSUs and RSAs, and the ESPP, calculated using the treasury stock method. The calculation of diluted shares outstanding excludes securities where the combination of the exercise or purchase price (in the case of options and the ESPP) and the associated unrecognized compensation expense is greater than the average market price of Class A common shares because the inclusion of these securities would be anti-dilutive.
There were approximately 3.3 million and 3.6 million potential shares that were anti-dilutive and excluded from the computation of diluted shares outstanding during the thirteen weeks ended April 30, 2022and May 1, 2021. There were 0 potentially dilutive securities outstanding during the thirteen weeks ended May 2, 2020.
For periods prior to the Company’s conversion to a Delaware corporation in January 2021, the Company has retrospectively presented net loss per share as if the conversion had occurred at the beginning of the earliest period presented. The weighted average shares used in computing net loss per Class A and B-1 common share in these periods are based on the number of Common Series A and Common Series B Units of PET Acquisition LLC held by members. For periods prior to the conversion, these calculations do not include the 55.2 million shares of Class A common stock issued in the Company’s initial public offering.respectively.
8.6. Commitments and Contingencies
COVID-19
The COVID-19 pandemic has been a highly disruptive economic and societal event that has affected the Company’s business and has had a significant impact on consumer shopping behavior. To serve pet parents while also providing for the safety of employees, the Company has adapted certain aspects of the business. Throughout the pandemic, the Company has monitored the rapidly evolving situation and will continue to adapt its operations to (i) address federal, state and local standards, (ii) meet the needs of pets and pet parents, and (iii) implement standards that the Company believes to be in the best interests of the safety and well-being of its employees and customers. The duration and severity of the pandemic remains uncertain.
Litigation
The Company is involved in legal proceedings and is subject to other claims and litigation, in each case, arising in the ordinary course of its business. The Company has made accruals with respect to certain of these matters, where appropriate, which are reflected in the Company’s condensed consolidated financial statements but are not, individually or in the aggregate, considered material. For other matters, the Company has not made accruals because
management has not yet determined that a loss is probable or because the amount of loss cannot be reasonably estimated. While the ultimate outcome of the matters cannot be determined, the Company currently does not expect that these matters will have a material adverse effect on its condensed consolidated financial statements. The outcome of any litigation is inherently uncertain, however, and if decided adversely to the Company, or if the Company determines that settlement of particular litigation is appropriate, the Company may be subject to liability that could have a material adverse effect on its condensed consolidated financial statements.
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and the accompanying notes included elsewhere in this Quarterly Report on Form 10-Q (this “Form 10-Q”), as well as the corresponding Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in our Annual Report on Form 10-K for the fiscal year ended January 30, 202129, 2022 (the “2020“2021 Form 10-K”). The discussion and analysis below containcontains certain forward-looking statements about our business and operations that are subject to the risks, uncertainties, and other factors describedreferred to in the sections entitled “Risk Factors” in Part I, Item 1A in the 2020 Form 10-K and Part II, Item 1A, in“Risk Factors” of this Form 10-Q. These risks, uncertainties, and other factors could cause our actual results to differ materially from those expressed in, or implied by, the forward-looking statements. Please read The risks described in this Form 10-Q and in other documents we file from time to time with the U.S. Securities and Exchange Commission (the “SEC”), including the section entitled “Cautionary Note Regarding Forward-Looking“Forward-Looking Statements” in the 2020this Form 10-K10-Q, should be carefully reviewed. All amounts herein are unaudited.
Overview
Founded in 1965, Petco Health and Wellness Company, Inc. (“Petco”, the “Company”, “we”, “our” and “us”) is a category-defining health and wellness company focused on improving the lives of pets, pet parents, and our own partners. Since our founding in 1965, weWe have been striving toconsistently set new standards in pet care while delivering comprehensive pet wellness solutions through our products, services and services,solutions, and creating communities that deepen the pet-pet parent bond. Over the last threeIn recent years, our world-class leadership team and our dedicated and passionate partnerswe have transformed theour business formfrom a successful yet traditional retailer to a disruptive, fully integrated, digital-focusedomnichannel provider of holistic pet health and wellness offerings, including premium nutrition, products, services and veterinary care. We operateThrough our integrated ecosystem, we provide our over 24 million total active customers with a comprehensive offering of differentiated products and services to fulfill their pets’ health and wellness needs through our more than 1,500 Petco locations acrosspet care centers in the U.S., Mexico, and Puerto Rico including a growing network of 137more than 200 in-store veterinary hospitals, our digital channel and offer a complete online resource for pet health and wellness at petco.com and on the Petco app.our flexible fulfillment options.
Our multichannel, go-to-market strategy is powered by a multi-channel platform that integrates our strong digital presenceassets with aour nationwide physical network.footprint to meet the needs of pet parents who are looking for a single source for all their pet’s needs. Our e-commerce site and personalized mobile app serve as a hubhubs for pet parents to manage their pets’ health, wellness, and merchandise needs, while enabling them to shop wherever, whenever, and however they want. By leveraging anour extensive physical network of pet care centers, we are able to offer aour comprehensive product and service offering in a localized manner with a meaningful last-mile advantage over much of our competition. The full value of our health and wellness ecosystem is realized for customers through our Vital Care membership program. From the competition.nutrition and supplies pets need each day, to the services that keep them at optimal health, Vital Care makes it easier and more affordable for pet parents to care for their pet’s whole health all in one place.
We strive to be a truly unique company, one that is saving and improving millions of pet lives and tangibly improving the lives of pet parents and the partners who work for us, while at the same time executing our differentiated strategy with excellence. In tandem with Petco Love (formerly the Petco Foundation), an independent nonprofit organization, we work with and support thousands of local animal welfare groups across the country and, through in-store adoption events, we have helped find homes for more than 6.5 million animals.
ImpactMacroeconomic factors, including the prolonged COVID-19 pandemic, inflationary pressures, global supply chain constraints and global economic and geopolitical developments, have varying impacts on our results of operations that are difficult to isolate and quantify. We cannot predict the duration or ultimate severity of these macroeconomic factors or the ultimate impact on the broader economy or our operations and liquidity. Please refer to the risk factors referred to in Part II, Item 1A, “Risk Factors” of this Form 10-Q.
In regard to the COVID-19 Pandemic on Our Business
The COVID-19 pandemic, has impacted every aspect of the economy. Asas an essential retailer, all of our pet care centers have remained open, some with limited or suspended services, as we are the grocery store, pharmacy, and doctor’s office for many of our nation’s pets. Market data indicatesThe pandemic has influenced certain trends that with more of the working population staying home, there has been an increase in pet ownership and the percentage of disposable income spent on home-related goods and services, including pet care. Overall, this macroeconomic trend has continued tohave favorably impactimpacted our business results to date, with millions of additional new pets welcomed into homes that need to be fed, groomed and vaccinated for years to come, but the possible sustained spread or resurgencecontinued proliferation of the pandemic,COVID-19, and any government response thereto, increases the uncertainty regarding potential economic conditions that could impact our business in the future.
We cannot predict the duration or severity of COVID-19 or its ultimate impact on the broader economy or our operations and liquidity. Please refer to the risk factors described in the sections entitled “Risk Factors” in Part I, Item 1A in the 2020 Form 10-K and Part II, Item 1A in this Form 10-Q.
How We Assess the Performance of Our Business
In assessing our performance, we consider a variety of performance and financial measures, including the following:
Comparable Sales
Comparable sales is an important measure throughout the retail industry and includes both retail and digital sales of products and services. A new location or digital site is included in comparable sales beginning on the first day of the fiscal month following 12 full fiscal months of operation and is subsequently compared to like time periods from the previous year. Relocated pet care centers become comparable pet care centers on the first day of operation if the original pet care center was open longer than 12 full fiscal months. If, during the period presented, a pet care center was closed, sales from that pet care center are included up to the first day of the month of closing. There may be variations in the way in which some of our competitors and other retailers calculate comparable sales. As a result, data in this filing regarding our comparable sales may not be comparable to similar data made available by other retailers.
Comparable sales allow us to evaluate how our overall ecosystem is performing by measuring the change in period-over-period net sales from locations and digital sites that have been open for the applicable period. We intend to improve comparable sales by continuing initiatives aimed to increase customer retention, frequency of visits, and basket size. General macroeconomic and retail business trends are also a key driver of changes in comparable sales.
Non-GAAP Financial Measures
Management and our board of directors review, in addition to GAAP (as defined herein) measures, certain non-GAAP financial measures, including Adjusted EBITDA and Free Cash Flow, and Net Debt, to evaluate our operating performance, generate future operating plans, and make strategic decisions regarding the allocation of capital. Further explanations of ourthese non-GAAP measures, along with reconciliations to their most comparable GAAP measures, are presented below under “Reconciliation of Non-GAAP Financial Measures to GAAP Measures.”
Executive Summary
Our business transformation initiatives, accelerated by an increase in pet ownership and a shift in customer discretionary spend toward the pet category,preferences towards products and services focused on health and wellness, have driven strong top-top and bottom-line growth in our business. Comparing the thirteen weeks ended May 1, 2021April 30, 2022 with the thirteen weeks ended May 2, 2020,1, 2021 (unless otherwise noted), we achieved the following results:
| • | an increase in net sales from |
| • | comparable sales growth of |
| • | an increase in operating income from |
| • | an increase in net income |
| • | an increase in Adjusted EBITDA from |
|
|
For a description of our non-GAAP measures and reconciliations to their most comparable GAAP measures, please read the section below titled “Reconciliation of Non-GAAP Financial Measures to GAAP Measures.”
Results of Operations
The following tables summarize our results of operations and the percent of net sales of line items included in our consolidated statements of operations (dollars in thousands):
|
| Thirteen weeks ended |
|
| Thirteen weeks ended |
| ||||||||||
|
| May 1, 2021 |
|
| May 2, 2020 |
|
| April 30, 2022 |
|
| May 1, 2021 |
| ||||
Net sales |
| $ | 1,414,994 |
|
| $ | 1,113,521 |
|
| $ | 1,475,991 |
|
| $ | 1,414,994 |
|
Cost of sales |
|
| 818,009 |
|
|
| 647,239 |
|
|
| 868,317 |
|
|
| 818,009 |
|
Gross profit |
|
| 596,985 |
|
|
| 466,282 |
|
|
| 607,674 |
|
|
| 596,985 |
|
Selling, general and administrative expenses |
|
| 549,236 |
|
|
| 449,917 |
|
|
| 557,735 |
|
|
| 549,236 |
|
Operating income |
|
| 47,749 |
|
|
| 16,365 |
|
|
| 49,939 |
|
|
| 47,749 |
|
Interest income |
|
| (21 | ) |
|
| (184 | ) |
|
| (20 | ) |
|
| (21 | ) |
Interest expense |
|
| 20,529 |
|
|
| 60,808 |
|
|
| 19,634 |
|
|
| 20,529 |
|
Loss on extinguishment and modification of debt |
|
| 20,838 |
|
|
| — |
|
|
| — |
|
|
| 20,838 |
|
Income (loss) before income taxes and income from equity method investees |
|
| 6,403 |
|
|
| (44,259 | ) | ||||||||
Income tax expense (benefit) |
|
| 2,679 |
|
|
| (10,555 | ) | ||||||||
Other non-operating income |
|
| (314 | ) |
|
| — |
| ||||||||
Income before income taxes and income from equity method investees |
|
| 30,639 |
|
|
| 6,403 |
| ||||||||
Income tax expense |
|
| 10,000 |
|
|
| 2,679 |
| ||||||||
Income from equity method investees |
|
| (2,425 | ) |
|
| (332 | ) |
|
| (3,163 | ) |
|
| (2,425 | ) |
Net income (loss) |
|
| 6,149 |
|
|
| (33,372 | ) | ||||||||
Net income |
|
| 23,802 |
|
|
| 6,149 |
| ||||||||
Net loss attributable to noncontrolling interest |
|
| (1,411 | ) |
|
| (2,204 | ) |
|
| (891 | ) |
|
| (1,411 | ) |
Net income (loss) attributable to Class A and B-1 common stockholders |
| $ | 7,560 |
|
| $ | (31,168 | ) | ||||||||
Net income attributable to Class A and B-1 common stockholders |
| $ | 24,693 |
|
| $ | 7,560 |
|
|
| Thirteen weeks ended |
| |||||
|
| April 30, 2022 |
|
| May 1, 2021 |
| ||
Net sales |
|
| 100.0 | % |
|
| 100.0 | % |
Cost of sales |
|
| 58.8 |
|
|
| 57.8 |
|
Gross profit |
|
| 41.2 |
|
|
| 42.2 |
|
Selling, general and administrative expenses |
|
| 37.8 |
|
|
| 38.8 |
|
Operating income |
|
| 3.4 |
|
|
| 3.4 |
|
Interest income |
|
| (0.0 | ) |
|
| (0.0 | ) |
Interest expense |
|
| 1.3 |
|
|
| 1.4 |
|
Loss on extinguishment and modification of debt |
|
| — |
|
|
| 1.5 |
|
Other non-operating income |
|
| (0.0 | ) |
|
| — |
|
Income before income taxes and income from equity method investees |
|
| 2.1 |
|
|
| 0.5 |
|
Income tax expense |
|
| 0.7 |
|
|
| 0.3 |
|
Income from equity method investees |
|
| (0.2 | ) |
|
| (0.2 | ) |
Net income |
|
| 1.6 |
|
|
| 0.4 |
|
Net loss attributable to noncontrolling interest |
|
| (0.1 | ) |
|
| (0.1 | ) |
Net income attributable to Class A and B-1 common stockholders |
|
| 1.7 | % |
|
| 0.5 | % |
|
| Thirteen weeks ended |
| |||||
|
| May 1, 2021 |
|
| May 2, 2020 |
| ||
Net sales |
|
| 100.0 | % |
|
| 100.0 | % |
Cost of sales |
|
| 57.8 |
|
|
| 58.1 |
|
Gross profit |
|
| 42.2 |
|
|
| 41.9 |
|
Selling, general and administrative expenses |
|
| 38.8 |
|
|
| 40.4 |
|
Operating income |
|
| 3.4 |
|
|
| 1.5 |
|
Interest income |
|
| 0.0 |
|
|
| 0.0 |
|
Interest expense |
|
| 1.4 |
|
|
| 5.5 |
|
Loss on extinguishment and modification of debt |
|
| 1.5 |
|
|
| — |
|
Income (loss) before income taxes and income from equity method investees |
|
| 0.5 |
|
|
| (4.0 | ) |
Income tax expense (benefit) |
|
| 0.3 |
|
|
| (0.9 | ) |
Income from equity method investees |
|
| (0.2 | ) |
|
| (0.1 | ) |
Net income (loss) |
|
| 0.4 |
|
|
| (3.0 | ) |
Net loss attributable to noncontrolling interest |
|
| (0.1 | ) |
|
| (0.2 | ) |
Net income (loss) attributable to Class A and B-1 common stockholders |
|
| 0.5 | % |
|
| (2.8 | )% |
|
| Thirteen weeks ended |
|
| Thirteen weeks ended |
| ||||||||||
|
| May 1, 2021 |
|
| May 2, 2020 |
|
| April 30, 2022 |
|
| May 1, 2021 |
| ||||
Operational Data: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comparable sales increase (decrease) |
|
| 28.4 | % |
|
| 2.1 | % | ||||||||
Comparable sales increase |
|
| 5.1 | % |
|
| 28.4 | % | ||||||||
Total pet care centers at end of period |
|
| 1,453 |
|
|
| 1,476 |
|
|
| 1,427 |
|
|
| 1,453 |
|
Total pet care centers with veterinarian practices at end of period |
|
| 137 |
|
|
| 89 |
| ||||||||
Adjusted EBITDA (in thousands) |
| $ | 125,746 |
|
| $ | 86,836 |
|
| $ | 132,551 |
|
| $ | 125,746 |
|
Thirteen Weeks Ended May 1, 2021April 30, 2022 Compared with Thirteen Weeks Ended May 2, 20201, 2021
Net Sales and Comparable Sales
| Thirteen weeks ended |
| |||||||||||||
(dollars in thousands) | April 30, 2022 |
|
| May 1, 2021 |
|
| $ Change |
|
| % Change |
| ||||
Consumables | $ | 685,930 |
|
| $ | 595,132 |
|
| $ | 90,798 |
|
|
| 15.3 | % |
Supplies and companion animals |
| 599,179 |
|
|
| 658,172 |
|
|
| (58,993 | ) |
|
| (9.0 | %) |
Services and other |
| 190,882 |
|
|
| 161,690 |
|
|
| 29,192 |
|
|
| 18.1 | % |
Net sales | $ | 1,475,991 |
|
| $ | 1,414,994 |
|
| $ | 60,997 |
|
|
| 4.3 | % |
Net sales increased $301.5$61.0 million, or 27.1%4.3%, to $1.48 billion in the thirteen weeks ended April 30, 2022 compared to net sales of $1.41 billion in the thirteen weeks ended May 1, 2021, compared to net sales of $1.11 billion in the thirteen weeks ended May 2, 2020, driven by a 28.4%5.1% increase in our comparable sales. Our sales growth period-over-period was driven by our strong execution and uniquedifferentiated model across digital and in our pet care centers, coupled with an increase in new pet ownership associated with the COVID-19 pandemic and benefits from government stimulus payments. Pet care centers delivered growth of 26.1% driven by ana resulting increase in sales to meet the needs of these pet adoptions and more customer trafficparents. Net sales during the thirteen weeks ended April 30, 2022 were impacted by inflation, as we have taken selective pricing actions to offset cost increases on some vendor-supplied product.
The increase in our centers. Our e-commerce and digitalconsumables sales increased 21.2%, lapping strong digital sales growthbetween the periods was driven in the same period last year at the start of the COVID-19 pandemic. This growth is drivenpart by the increase in new pets, as well as our integrated offerings, which include buy onlinestrategic investments in customer acquisition and pick upretention, continued expansion of our product assortment and a shift to more premium consumables. The decrease in store, curbside pick-up, ship-from-store, repeat delivery, and same day delivery.
Suppliessupplies and companion animal sales increased 33.3% between the periodsanimals is due in part to a strong stimulus driven thirteen week period ended May 1, 2021 and a decrease in spending on certain non-essential items. We have experienced some softening in discretionary spend although our total merchandise mix remains strong. due to increases in pet ownership and shifts in disposable income toward pets. Dog and cat food sales increased 13.2% and services and other sales increased 71.9% between the periods, respectively. The increase in services and other was due in part to the increase in new pets, growth in our membership offerings like Vital Care, and growth in our veterinary hospital business in which we now operate over 200 veterinary hospitals.
For the thirteen weeks ended April 30, 2022, pet care center merchandise delivered growth of 1.6% with the addition of 48 new hospitals period-over-period coupled with headwinds experiencedstrong growth in consumables. E-commerce and digital sales increased 10.5% during the thirteen weeks ended May 2, 2020 withApril 30, 2022, driven by strength in our online initiatives such as repeat delivery, BOPUS, ship from store and the temporary suspensionmobile app. Services sales, which include veterinary hospitals, increased 18.9% during the thirteen weeks ended April 30, 2022, reflecting expansion of our training,veterinary hospital footprint and strong growth in veterinary and grooming and vaccination clinic services while stay-at-home orders were in place.customers.
Cost of Goods Sold and Gross Profit
Gross profit increased $130.7$10.7 million, or 28.0%1.8%, to $597.0$607.7 million in the thirteen weeks ended May 1, 2021April 30, 2022 compared to gross profit of $466.3$597.0 million for the thirteen weeks ended May 2, 2020.1, 2021. As a percentage of sales, our gross profit rate improved slightly atwas 41.2% for the thirteen weeks ended April 30, 2022 compared with 42.2% for the thirteen weeks ended May 1, 2021 compared2021. The decrease in gross profit rate between the periods was primarily due to 41.9% forthe mix impact of strong consumables sales during the thirteen weeks ended May 2, 2020. The increaseApril 30, 2022. While the strong consumables mix impacts the gross margin rate, the average consumables customer has a higher lifetime value than most other categories of customer. Sales channel impacts driven by strength in our digital, services and vet business, and moderate increases in distribution costs also contributed to the decrease in gross profit was duerate during the thirteen weeks ended April 30, 2022 as compared to the overall increase in net sales across key business areas, which was partially offset by an increase in supply chain expenses to support higher sales volume.prior year period.
Selling, General and Administrative (“SG&A”) Expenses
SG&A expenses increased $99.3$8.5 million, or 22.1%1.5%, to $557.7 million for the thirteen weeks ended April 30, 2022 compared to $549.2 million for the thirteen weeks ended May 1, 2021 compared to $449.9 million for the thirteen weeks ended May 2, 2020.2021. As a percentage of net sales, SG&A expenses improved from 40.4%were 37.8% for the thirteen weeks ended May 2, 2020 toApril 30, 2022 compared with 38.8% for the thirteen weeks ended May 1, 2021, reflecting operating leverage from net sales growth. The increase in SG&A expenses period-over-period was drivento support our growth as we continue to invest in infrastructure and our people. The growth was partially offset by a $40.7 million increasedecrease in advertising expenses to support the acceleration of our sales growth. The remainder of the increase was predominatelyperiod-over-period primarily due to higher incentive compensationextensive investments that were made during the thirteen week period ended May 1, 2021 for corporateour rebranding campaign, inclusive of a TV launch and field employees along with increased variable costs associated with our higher sales growth. In addition, SG&A expenses were lower foradvertisements.
Interest Expense
Interest expense decreased $0.9 million, or 4.4%, to $19.6 million in the thirteen weeks ended May 2, 2020 due to cost containment measures implemented at the start of the COVID-19 pandemic.
Interest Expense
Interest expense decreased $40.3 million, or 66.2%, toApril 30, 2022 compared with $20.5 million in the thirteen weeks ended May 1, 2021 compared with $60.8 million in the thirteen weeks ended May 2, 2020.2021. The decrease was primarily driven by quarterly principal payments on the redemption/cancellation of the Floating Rate Senior Notes and the 3.00% Senior Notes (each as definedFirst Lien Term Loan, which resulted in a lower outstanding balance. For more information on these obligations, refer to Note 3, “Senior Secured Credit Facilities,,” to the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q) and repayment of a portion of our then-outstanding senior secured term loan facility (the “Amended Term Loan Facility”) in connection with our initial public offering. In March 2020, we borrowed $250.0 million on our then-outstanding senior secured asset-based revolving credit facility (the “Amended Revolving Credit Facility”) as a precautionary measure given the uncertainty of the macroeconomic environment at the start of the COVID-19 pandemic. We subsequently repaid the amount in full in the second quarter of fiscal 2020 and had no borrowings outstanding on the Amended Revolving Credit Facility as of January 30, 2021..
Loss on Extinguishment and Modification of Debt
Loss on extinguishment and modification of debt was $20.8 million for the thirteen weeks ended May 1, 2021. This loss was recognized in conjunction with the March 4, 2021 debt refinancing transaction described above.of the Amended Term Loan Facility and Amended Revolving Credit Facility. There was no loss on debt extinguishment and modification for the thirteen weeks ended May 2, 2020.April 30, 2022. For more
information regarding these activities, refer to Note 3, “Senior Secured Credit Facilities,” to the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
Other Non-Operating Income
Other non-operating income was $0.3 million for the thirteen weeks ended April 30, 2022. This income relates to non-cash gains from the remeasurement of the fair value of our investment in Rover Group, Inc. There was no other non-operating income recognized during the thirteen weeks ended April 30, 2022. For more information regarding this activity, refer to Note 4, “Fair Value Measurements,” to the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
Income Tax Expense (Benefit)
Our effective tax rate was 26.2%28.8% resulting in income tax expense of $10.0 million for the thirteen weeks ended May 1, 2021,April 30, 2022, compared to an effective tax rate of 26.2% resulting in income tax expense of $2.7 million compared to an effective tax rate of 25.8% and income tax benefit of $10.6 million for the thirteen weeks ended May 2, 2020. The increase in effective tax rate is primarily driven by an increase in earnings along with an increase in stock-based compensation for the thirteen weeks ended May 1, 2021. The increase in effective tax rate for the thirteen weeks ended April 30, 2022 is primarily driven by an increase in nondeductible executive compensation subject to Section 162(m) of the Internal Revenue Code.
Reconciliation ofNon-GAAP Financial Measuresto GAAP Measures
The following information provides definitions and reconciliations of certain non-GAAP financial measures to the most directly comparable financial measures calculated and presented in accordance with GAAP. Such non-GAAP financial measures are not calculated in accordance with GAAP and should not be considered superior to, as a substitute for or alternative to, and should be considered in conjunction with, the most comparable GAAP measures. The non-GAAP financial measures presented may differ from similarly-titled measures used by other companies.
Adjusted EBITDA
We present Adjusted EBITDA, a non-GAAP financial measure, because we believe it enhances an investor’s understanding of our financial and operational performance by excluding certain material non-cash items, unusual or non-recurring items that we do not expect to continue in the future, and certain other adjustments we believe are or are not reflective of our ongoing operations and performance. Adjusted EBITDA enables operating performance to be reviewed across reporting periods on a consistent basis. We use Adjusted EBITDA as one of the principal measures to evaluate and monitor our operating financial performance and to compare our performance to others in our industry. We also use Adjusted EBITDA in connection with establishing discretionary annual incentive compensation targets, to make budgeting decisions, to make strategic decisions regarding the allocation of capital, and to report our quarterly results as defined in our debt agreements, although under such agreements the measure is calculated differently and is used for different purposes.
Adjusted EBITDA is not a substitute for net income (loss), the most comparable GAAP measure, and is subject to a number of limitations as a financial measure, so it should be used in conjunction with GAAP financial measures and not in isolation. There can be no assurances that we will not modify the presentation of Adjusted EBITDA in the future. In addition, other companies in our industry may define Adjusted EBITDA differently,
limiting its usefulness as a comparative measure. Refer to Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Reconciliation of Non-GAAP Financial Measures to GAAP Measures” included in the 20202021 Form 10-K for more information regarding how we define Adjusted EBITDA.
The table below reflects the calculation of Adjusted EBITDA and Adjusted EBITDA Margin after taking into account net sales for the periods presented:
|
| Thirteen weeks ended |
|
| Thirteen weeks ended |
| ||||||||||
|
| May 1, 2021 |
|
| May 2, 2020 |
| ||||||||||
Reconciliation of Net Income (Loss) Attributable to Class A and B-1 Common Stockholders to Adjusted EBITDA |
|
|
|
|
|
|
|
| ||||||||
Net income (loss) attributable to Class A and B-1 common stockholders |
| $ | 7,560 |
|
| $ | (31,168 | ) | ||||||||
(dollars in thousands) |
| April 30, 2022 |
|
| May 1, 2021 |
| ||||||||||
Net income attributable to Class A and B-1 common stockholders |
| $ | 24,693 |
|
| $ | 7,560 |
| ||||||||
Interest expense, net |
|
| 20,508 |
|
|
| 60,624 |
|
|
| 19,614 |
|
|
| 20,508 |
|
Income tax expense (benefit) |
|
| 2,679 |
|
|
| (10,555 | ) | ||||||||
Income tax expense |
|
| 10,000 |
|
|
| 2,679 |
| ||||||||
Depreciation and amortization |
|
| 41,607 |
|
|
| 43,567 |
|
|
| 46,967 |
|
|
| 41,607 |
|
Income from equity method investees |
|
| (2,425 | ) |
|
| (332 | ) |
|
| (3,163 | ) |
|
| (2,425 | ) |
Loss on debt extinguishment and modification |
|
| 20,838 |
|
|
| — |
|
|
| — |
|
|
| 20,838 |
|
Asset impairments and write offs |
|
| 947 |
|
|
| 3,409 |
|
|
| 162 |
|
|
| 947 |
|
Equity-based compensation |
|
| 11,604 |
|
|
| 2,305 |
|
|
| 12,222 |
|
|
| 11,604 |
|
Other non-operating income |
|
| (314 | ) |
|
| — |
| ||||||||
Mexico joint venture EBITDA (1) |
|
| 6,006 |
|
|
| 4,019 |
|
|
| 6,778 |
|
|
| 6,006 |
|
Store pre-opening expenses |
|
| 4,029 |
|
|
| 1,908 |
|
|
| 3,359 |
|
|
| 4,029 |
|
Store closing expenses |
|
| 1,103 |
|
|
| 1,027 |
|
|
| 1,860 |
|
|
| 1,103 |
|
Severance |
|
| 818 |
|
|
| 3,084 |
| ||||||||
Non-cash occupancy-related costs (2) |
|
| 1,139 |
|
|
| 7,200 |
|
|
| 2,194 |
|
|
| 1,139 |
|
Non-recurring costs (3) |
|
| 9,333 |
|
|
| 1,748 |
| ||||||||
Acquisition-related integration costs (3) |
|
| 2,236 |
|
|
| — |
| ||||||||
Other costs (4) |
|
| 5,943 |
|
|
| 10,151 |
| ||||||||
Adjusted EBITDA |
| $ | 125,746 |
|
| $ | 86,836 |
|
| $ | 132,551 |
|
| $ | 125,746 |
|
Net sales |
| $ | 1,414,994 |
|
| $ | 1,113,521 |
|
| $ | 1,475,991 |
|
| $ | 1,414,994 |
|
Net margin |
|
| 0.5 | % |
|
| (2.8 | )% |
|
| 1.7 | % |
|
| 0.5 | % |
Adjusted EBITDA Margin |
|
| 8.9 | % |
|
| 7.8 | % |
|
| 9.0 | % |
|
| 8.9 | % |
(1) | Mexico joint venture EBITDA represents 50% of the entity’s operating results for the periods presented, as adjusted to reflect the results on a basis comparable to our Adjusted EBITDA. In the financial statements, this joint venture is accounted for as an equity method investment and reported net of depreciation and income taxes. Because such a presentation would not reflect the adjustments made in our calculation of Adjusted EBITDA, we include our 50% interest in our Mexico joint venture on an Adjusted EBITDA basis to ensure consistency. The table below presents a reconciliation of Mexico joint venture net income to Mexico joint venture EBITDA: |
|
| Thirteen weeks ended |
|
| Thirteen weeks ended |
| ||||||||||
(dollars in thousands) |
| May 1, 2021 |
|
| May 2, 2020 |
|
| April 30, 2022 |
|
| May 1, 2021 |
| ||||
Net income |
| $ | 4,849 |
|
| $ | 728 |
|
| $ | 5,133 |
|
| $ | 4,849 |
|
Depreciation |
|
| 3,400 |
|
|
| 3,154 |
|
|
| 4,294 |
|
|
| 3,400 |
|
Income tax expense |
|
| 2,780 |
|
|
| 1,295 |
|
|
| 2,997 |
|
|
| 2,780 |
|
Foreign currency (gain) loss |
|
| (145 | ) |
|
| 1,557 |
| ||||||||
Interest expense (income), net |
|
| 1,128 |
|
|
| 1,304 |
| ||||||||
Foreign currency gain |
|
| (64 | ) |
|
| (145 | ) | ||||||||
Interest expense, net |
|
| 1,196 |
|
|
| 1,128 |
| ||||||||
EBITDA |
| $ | 12,012 |
|
| $ | 8,038 |
|
| $ | 13,556 |
|
| $ | 12,012 |
|
50% of EBITDA |
| $ | 6,006 |
|
| $ | 4,019 |
|
| $ | 6,778 |
|
| $ | 6,006 |
|
(2) | Non-cash occupancy-related costs include the difference between cash and straight-line rent for all periods. |
(3) |
|
(4) | Other costs include: |
| We define net margin as net income |
Free Cash Flow
Free Cash Flow is a non-GAAP financial measure that is calculated as net cash provided by operationsoperating activities less cash paid for fixed assets. Management believes that Free Cash Flow, which measures our ability to
generate additional cash from our business operations, is an important financial measure for use in evaluating the Company’s financial performance.
Although other companies report their free cash flow, numerous methods exist for calculating a company’s free cash flow. As a result, the method used by the Company to calculate our Free Cash Flow may differ from the methods used by other companies to calculate their free cash flow.
The table below reflects the calculation of Free Cash Flow for the periods presented:
|
| Thirteen weeks ended |
| |||||
|
| May 1, 2021 |
|
| May 2, 2020 |
| ||
(dollars in thousands) |
| (52 weeks) |
|
| (52 weeks) |
| ||
Net cash provided by (used in) operating activities |
| $ | 115,002 |
|
| $ | (32,289 | ) |
Cash paid for fixed assets |
|
| (47,351 | ) |
|
| (27,895 | ) |
Free Cash Flow |
| $ | 67,651 |
|
| $ | (60,184 | ) |
Net Debt
Net Debt is a non-GAAP financial measure that is calculated as the sum of current and non-current debt, less cash and cash equivalents. Management considers this adjustment useful because it reduces the volatility of total debt caused by fluctuations between cash paid against the Company’s revolving credit facility and cash held on hand in cash and cash equivalents.
Although other companies report their net debt, numerous methods exist for calculating a company’s net debt. As a result, the method used by the Company to calculate our Net Debt may differ from the methods used by other companies to calculate their net debt.
The table below reflects the calculation of Net Debt for the periods presented:
(dollars in thousands) |
| May 1, 2021 |
|
| May 2, 2020 |
| ||
Total debt: |
|
|
|
|
|
|
|
|
Senior secured credit facilities, net, including current portion |
| $ | 1,666,509 |
|
| $ | 2,647,461 |
|
Senior notes, net |
|
| — |
|
|
| 866,952 |
|
Finance leases, including current portion |
|
| 16,409 |
|
|
| 15,504 |
|
Total debt |
| $ | 1,682,918 |
|
| $ | 3,529,917 |
|
Less: cash and cash equivalents |
|
| (174,034 | ) |
|
| (341,506 | ) |
Net Debt |
| $ | 1,508,884 |
|
| $ | 3,188,411 |
|
Adjusted EBITDA |
| $ | 523,258 |
|
| $ | 413,651 |
|
Net Debt / Adjusted EBITDA ratio |
| 2.9x |
|
| 7.7x |
|
|
| Thirteen weeks ended |
| |||||
|
| April 30, 2022 |
|
| May 1, 2021 |
| ||
(dollars in thousands) |
|
|
|
|
|
|
|
|
Net cash provided by operating activities |
| $ | 57,519 |
|
| $ | 115,002 |
|
Cash paid for fixed assets |
|
| (65,910 | ) |
|
| (47,351 | ) |
Free Cash Flow |
| $ | (8,391 | ) |
| $ | 67,651 |
|
Liquidity and Capital Resources
Overview
Our primary sources of liquidity are funds generated by operating activities and available capacity for borrowings on our $500 million secured asset-based revolving credit facility maturing March 4, 2026 (the “ABL Revolving Credit Facility”). Our ability to fund our operations, to make planned capital investments, to make scheduled debt payments and to repay or refinance indebtedness depends on our future operating performance and cash flows, which are subject to prevailing economic conditions and financial, business, and other factors, some of which are beyond our control. Our liquidity as of May 1, 2021April 30, 2022 was $594.5$629.7 million, inclusive of cash and cash equivalents of $174.0$190.9 million and $420.5$438.8 million of availability on the ABL Revolving Credit Facility.
We are a party to contractual obligations involving commitments to make payments to third parties. These obligations impact our short-term and long-term liquidity and capital resource needs. We believe that our current resources, together with anticipated cash flows from operations and borrowing capacity under the ABL Revolving Credit Facility will be sufficient to finance our operations, meet our current cash requirements, and fund anticipated capital investments for at least the next 12 months. We may, however, seek additional financing to fund future growth or refinance our existing indebtedness through the debt capital markets, but we cannot be assured that such financing will be available on favorable terms, or at all.
We are a party to contractual obligations involving commitments to make payments to third parties. These obligations impact our short-term and long-term liquidity and capital resource needs. There have been no material changes to our contractual obligations as compared to those described in the 2020 Form 10-K, except for the debt refinancing transaction that occurred on March 4, 2021. For more information regarding our primary obligations,
refer to Note 3, “Senior Secured Credit Facilities,” to the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q for amounts outstanding as of May 1, 2021 related to our debt. Also refer to further discussion on our debt refinancing transaction in “Sources of Liquidity” below.
Cash Flows
The following table summarizes our consolidated cash flows:
|
| Thirteen weeks ended |
|
| Thirteen weeks ended |
| ||||||||||
(dollars in thousands) |
| May 1, 2021 |
|
| May 2, 2020 |
|
| April 30, 2022 |
|
| May 1, 2021 |
| ||||
|
| (52 weeks) |
|
| (52 weeks) |
| ||||||||||
Total cash provided by (used in): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating activities |
| $ | 115,002 |
|
| $ | (32,289 | ) |
| $ | 57,519 |
|
| $ | 115,002 |
|
Investing activities |
|
| (47,351 | ) |
|
| (27,895 | ) |
|
| (65,910 | ) |
|
| (47,351 | ) |
Financing activities |
|
| (7,213 | ) |
|
| 253,752 |
|
|
| (15,260 | ) |
|
| (7,213 | ) |
Net increase in cash, cash equivalents and restricted cash |
| $ | 60,438 |
|
| $ | 193,568 |
| ||||||||
Net (decrease) increase in cash, cash equivalents and restricted cash |
| $ | (23,651 | ) |
| $ | 60,438 |
|
Operating Activities
Our primary source of operating cash is sales of products and services to customers, which are substantially all on a cash basis, and therefore provide us with a significant source of liquidity. Our primary uses of cash in operating activities include: purchases of inventory; freight and warehousing costs; employee-related expenditures; occupancy-related costs for our pet care centers, distribution centers and corporate support centers; credit card fees; interest under our debt agreements; and marketing expenses. Net cash provided by operating activities is impacted by our net income (loss) adjusted for certain non-cash items, including: depreciation, amortization, impairments and write-offs; amortization of debt discounts and issuance costs; deferred income taxes; equity-based compensation; impairments of goodwill and intangible assets; other non-operating income; and the effect of changes in operating assets and liabilities.
Net cash provided by operating activities was $57.5 million in the thirteen weeks ended April 30, 2022 compared with net cash provided by operating activities of $115.0 million in the thirteen weeks ended May 1, 2021 compared with net cash used in operating activities of $32.3 million in the thirteen weeks ended May 2, 2020. 2021.
The increasedecrease in operating cash flow was due to strong operating performance and working capital benefit generateddriven by higher payroll, bonus and fringe benefits, an increase in cash paid for inventory driven by increased sales, as well as lowerand an increase in cash paid for interest payments due to the reductiontiming of debt balances in connection with the initial public offering andpayments following the refinancing transaction that occurred onin March 4, 2021 discussed under “Sources of Liquidity” below. The increasedecrease in operating cash flows between the periods was partially offset by higher payroll, bonus and fringeworking capital benefits driven by operating performance and pet care center appreciation bonuses, an increase in cash paid for inventory drivengenerated by higher inventory turns, an increase in cash paid on operating leases due to the timing of rent payments and an increase in advertising spend.
sales.
Investing Activities
Cash used in investing activities consists of capital expenditures, which in the thirteen weeks ended May 1, 2021April 30, 2022 and the thirteen weeks ended May 2, 20201, 2021 primarily supported our transformation initiatives. Net cash used in investing activities was $47.4$65.9 million and $27.9$47.4 million for the thirteen weeks ended April 30, 2022 and May 1, 2021, and May 2, 2020, respectively. The increase in capital expenditures between the periods is partiallywas predominately due to a reduction in capital expenditures put in place for the thirteen weeks ended May 2, 2020 at the start of the COVID-19 pandemic. The majoritybuild-out of our capital expenditures are discretionaryveterinary hospitals, investments in naturedigital assets and madeinnovation in response to expand our business.sales growth.
Financing Activities
Net cash used in financing activities was $7.2$15.3 million for the thirteen weeks ended May 1, 2021,April 30, 2022, compared with $253.8$7.2 million provided byused in financing activities in the thirteen weeks ended May 2, 2020.1, 2021.
Financing cash flows in the thirteen weeks ended April 30, 2022 primarily consisted of quarterly repayments on the term loan and payments for tax withholdings on stock-based awards.
Financing cash flows in the thirteen weeks ended May 1, 2021 primarily consisted of borrowings and repayments of debt in connection with the March 4, 2021 debt refinancing transaction.transaction discussed under “Sources of Liquidity” below. For more information regarding these activities, refer to Note 3 “Senior Secured Credit Facilities,” to the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
Financing cash flows in the thirteen weeks ended May 2, 2020 included a precautionary draw on the Amended Revolving Credit Facility of $250.0 million in March 2020 at the start of the COVID-19 pandemic. As operations stabilized and financial results improved, the balance was repaid in full in the second quarter of fiscal 2020.
Sources of Liquidity
Senior Secured Credit Facilities
As of January 30, 2021, the Company had $1,678.1 million outstanding on the Amended Term Loan Facility and no balance on the Amended Revolving Credit Facility, providing for senior secured financing of up to $500.0 million, subject to a borrowing base.
On March 4, 2021, the Company completed a refinancing transaction by repaying the Amended Term Loan Facility and entering into thea new $1,700 million secured term loan facility maturing on March 4, 2028 (the “First Lien Term Loan”) and the ABL Revolving Credit Facility, which matures on March 4, 2026 and has availability of up to $500.0 million, subject to a borrowing base. The refinancing transaction, in combination with the application of the proceeds from the Company’s initial public offering and other recapitalization transactions in connection therewith, reduced the Company’s total debt by 52.3% percent over the thirteen weeks ended May 2, 2020. Net Debt as a result of these transactions decreased $1,700 million or 52.7% to $1,500 million at May 1, 2021. Interest under the First Lien Term Loan is based on, at the Company’s option, either a base rate or Adjusted LIBOR, subject to a 0.75% floor, payable upon maturity of the LIBOR contract, in either case plus the applicable rate. The base rate is the greater of the bank prime rate, federal funds effective rate plus 0.5% or Adjusted LIBOR plus 1.0%. The applicable rate is 2.25% per annum for a base rate loan or 3.25% per annum for an Adjusted LIBOR loan. Principal payments are $4.25 million quarterly and commencecommenced on June 30, 2021. The terms under the ABL Revolving Credit Facility are substantially similar to those of the Amended Revolving Credit Facility.
For more information regarding this indebtedness, refer to Note 3, “Senior Secured Credit Facilities,” to the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
Derivative Instruments
In March 2016, the Company entered into a series of five interest rate cap agreements with four counterparties totaling $1,950.0 million to limit the maximum interest rate on a portion of the variable-rate debt and limit exposure to interest rate variability when three-month LIBOR exceeds 2.25%. The interest rate caps were accounted for as cash flow hedges, and changes in the fair value of the interest rate caps were reported as a component of accumulated other comprehensive income. The interest rate caps were settled in accordance with their contractual terms on January 29, 2021.
Critical Accounting Policies and Estimates
The preparation of our consolidated financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires us to make assumptions and estimates about future results and apply judgments that affect the reported amounts of assets, liabilities, net sales, expenses and related disclosures. We base our estimates and judgments on historical experience, current trends and other factors that we believe to be relevant at the time our consolidated financial statements are prepared. On an ongoing basis, we review the accounting policies, assumptions, estimates and judgments to ensure that our financial statements are presented fairly and in accordance with GAAP. However, because future events and their effects cannot be determined with certainty, actual results could differ from our assumptions and estimates, and such differences could be material.
There have been no material changes to our critical accounting policies and estimates as compared to the critical accounting policies and estimates described in the 20202021 Form 10-K.
Recent Accounting Pronouncements
Refer to Note 1, “Summary of Significant Accounting Policies,” to the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q for information regarding recently issued accounting pronouncements.
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
We are subject to market risks arising from transactions in the normal course of our business. These risks are primarily associated with interest rate fluctuations, as well as changes in our credit standing, based on the capital and credit markets, which are not predictable. We do not currently hold any instruments for trading purposes.
Interest Rate Risk
We are subject to interest rate risk in connection with the First Lien Term Loan and the ABL Revolving Credit Facility. As of May 1, 2021,April 30, 2022, we had $1,700.0$1,683.0 million outstanding under the First Lien Term Loan and no amounts outstanding under the ABL Revolving Credit Facility. The First Lien Term Loan and the ABL Revolving Credit Facility each bear interest at variable rates. An increase of 100 basis points in the variable rates on the First Lien Term Loan and the ABL Revolving Credit Facility as of May 1, 2021April 30, 2022 would have increased annual cash interest in the aggregate by approximately $17.2$17.1 million. As of May 1, 2021, the underlying interest rates on the First Lien Term Loan and the ABL Revolving Credit Facility were at the floor in the applicable agreements.
We cannot predict market fluctuations in interest rates and their impact on our debt, nor can there be any assurance that long-term fixed-rate debt will be available at favorable rates, if at all. Consequently, future results may differ materially from estimated results due to adverse changes in interest rates or debt availability.
Credit Risk
As of May 1, 2021,April 30, 2022, our cash and cash equivalents were maintained at major financial institutions in the United States, and our current deposits are likely in excess of insured limits. We believe these institutions have sufficient assets and liquidity to conduct their operations in the ordinary course of business with little or no credit risk to us.
Foreign Currency Risk
Substantially all of our business is currently conducted in U.S. dollars. We do not believe that an immediate 10% increase or decrease in the relative value of the U.S. dollar as compared to other currencies would have a material effect on our operating results.
Item 4. Controls and Procedures.
Management’s Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required financial disclosure.
As of the end of the period covered by this Form 10-Q, our management, under the supervision and with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures pursuant to Exchange Act Rules 13a-15(e) and 15d-15(e). Based upon this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of May 1, 2021.April 30, 2022.
Changes in Internal Control over Financial Reporting
This Form 10-Q does not include disclosure ofThere were no changes in our internal control over financial reporting during the quarter ended April 30, 2022, that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Limitations on the Effectiveness of Controls
Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives. Management does not expect, however, that our disclosure controls and procedures will prevent or detect all error and fraud. Any control system, no matter how well designed and operated, is based on certain assumptions and can provide only reasonable, not absolute, assurance that its objectives will be met. Further, no evaluation of controls can provide absolute assurance that misstatements due to a transition period established by ruleserror or fraud will not occur or that all control issues and instances of fraud, if any, within the SEC for newly public companies.Company have been detected.
PART II—OTHER INFORMATION
Item 1. Legal Proceedings.
See Note 8,6, “Commitments and Contingencies—LitigationContingencies,” to the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q for a description of legal proceedings, which is incorporated herein by reference.
Item 1A. Risk Factors.
Reference is made to Part I, Item 1A, “Risk Factors” included in the 20202021 Form 10-K for information concerning risk factors. Except as set forth below, thereThere have been no material changes with respect to the risk factors disclosed in our 2020 Form 10-K. The risk factors set forth below update, and should be read together with, the risk factors in our 20202021 Form 10-K. You should carefully consider such factors, which could materially and adversely affect our business, financial condition and/or future results.results of operations. The risks described in this Form 10-Q and in the 20202021 Form 10-K are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially and adversely affect our business, financial condition and/or results of operationoperations.
Risks Related to Our Business
The loss of any of our key merchandise vendors, or of any of our exclusive distribution arrangements with certain of our vendors, could negatively impact our business.
We purchase significant amounts of products from a number of vendors with limited supply capabilities. There can be no assurance that our current pet food or supply vendors will be able to accommodate our anticipated growth and expansion of our locations and e-commerce business. As a result of the disruptions resulting from COVID-19, some of our existing vendors have not been able to supply us with products in a timely or cost-effective manner. While these disruptions have so far proven to be temporary, an inability of our existing vendors to provide products or other product supply disruptions that may occur in the future could impair our business, financial condition, and results of operations. To date, vendor-related supply challenges have not had a material effect on our business or our sales and profitability. We do not maintain long-term supply contracts with any of our merchandise vendors. Any vendor could discontinue selling to us at any time. Although we do not materially rely on any particular vendor, the loss of any of our significant vendors of pet food, particularly premium pet food, or pet supplies that we offer could have a negative impact on our business, financial condition, and results of operations.
We continually seek to expand our base of pet food and supply vendors and to identify new pet products. If we are unable to identify or enter into distribution relationships with new vendors or to replace the loss of any of our existing vendors, we may experience a competitive disadvantage, our business may be disrupted, and our results of operations may be adversely affected.
Most of the premium pet food brands that we purchase are not widely carried in supermarkets, warehouse clubs, or mass merchants. If any premium pet food manufacturers were to make premium pet food products widely available in supermarkets or through mass merchants, or if the premium brands currently available to supermarkets and mass merchants were to increase their market share at the expense of the premium brands sold only through specialty pet food and supplies retailers, our ability to attract and retain customers or our competitive position may suffer. Further, if supermarkets, warehouse clubs, or mass merchants begin offering any of these premium pet food brands at lower prices, our sales and gross margin could be adversely affected.
Several of the pet food brands and product lines we currently purchase and offer for sale to our customers are not offered by our closest pet specialty competitor. However, in most cases, we have not entered into formal exclusivity agreements with the vendors for such brands. In the event these vendors choose to enter into distribution arrangements with other specialty pet retailers or other competitors our sales could suffer and our business could be adversely affected.
Our principal vendors currently provide us with certain incentives such as volume purchasing, trade discounts, cooperative advertising, and market development funds. A reduction or discontinuance of these incentives would increase our costs and could reduce our profitability.
Fluctuations in the prices and availability of certain commodities, such as grains and meat protein, could materially adversely affect our operating results.
The pet food and supplies industry is subject to risks related to increases in the price of and the availability of certain commodities used in the production of certain pet food and other pet-related products, specifically seed, wheat, and rice, as well as other materials that are used in certain pet accessories. Additionally, increased human and/or pet consumption or population increases may potentially limit the supply of or increase prices for certain meat proteins used in animal feed.
Historically, in circumstances where these price increases have resulted in our manufacturers or vendors increasing the costs we pay for our food products, we have been able to pass these increases on to customers. However, our ability to pass on increased purchase costs in the future will be significantly impacted by market conditions and competitive factors. If we are unable to pass on any increased purchase costs to customers, we may experience reduced margins, which could have a material adverse effect on our business, financial condition, and results of operations.
Risks Related to Legal and Regulatory Matters
We are subject to risks related to online payment methods and our Petco Pay promotional financing program.
We currently accept payments using a variety of methods, including credit cards, debit cards, PayPal, and gift cards. As we offer new payment options to consumers, we may be subject to additional regulations, compliance requirements, fraud, and other risks. For certain payment methods, we pay interchange and other fees, which may increase over time and raise our operating costs and lower profitability. As a merchant that accepts debit and credit cards for payment, we are subject to the Payment Card Industry (“PCI”) Data Security Standard (“PCI DSS”), issued by the PCI Council. PCI DSS contains compliance guidelines and standards with regard to our security surrounding the physical administrative and technical storage, processing, and transmission of individual cardholder data. By accepting debit cards for payment, we are also subject to compliance with American National Standards Institute data encryption standards and payment network security operating guidelines.
Failure to be PCI compliant or to meet other payment card standards may result in the imposition of financial penalties or the allocation by the card brands of the costs of fraudulent charges to us.
Additionally, the Fair and Accurate Credit Transactions Act requires systems that print payment card receipts to employ personal account number truncation so that the customer’s full account number is not viewable on the slip.
Further, as our business changes, we may be subject to different rules under existing standards, which may require new assessments that involve costs above what we currently pay for compliance. In the future, as we offer new payment options to consumers, including by way of integrating emerging mobile and other payment methods, we may be subject to additional regulations, compliance requirements, and fraud. If we fail to comply with the rules or requirements of any provider of a payment method we accept, if the volume of fraud in our transactions limits or terminates our rights to use payment methods we currently accept, or if a data breach occurs relating to our payment systems, we may, among other things, be subject to fines, legal proceedings, or higher transaction fees and may lose, or face restrictions placed upon, our ability to accept credit card payments from consumers or facilitate other types of online payments. If any of these events were to occur, our business, financial condition, and results of operations could be materially and adversely affected.
We also occasionally receive orders placed with fraudulent data. If we are unable to detect or control fraud, our liability for these transactions could harm our business, financial condition, and results of operations.
We offer promotional financing and credit cards issued by third-party banks that manage and directly extend credit to our customers through our Petco Pay program. Customers using Petco Pay can earn rewards for making purchases on the Petco-branded credit cards or receive extended payment terms and low interest financing on qualifying purchases. We believe Petco Pay will generate incremental revenue from customers who prefer the financing terms to other available forms of payment or otherwise need access to financing in order to make purchases. In addition, we earn profit- share income and share in any losses from certain of our banking partners based on the performance of the programs. The income or loss we earn in this regard is subject to numerous factors,
including the volume and value of transactions, the terms of promotional financing offers, bad debt rates, interest rates, the macroeconomic, regulatory and competitive environment, and expenses of operating the program. Adverse changes to any of these factors could impair our ability to offer Petco Pay to customers, reduce customer purchases, or impair our ability to earn income from sharing in the profits of the program.
In addition, the continued economic ramifications of COVID-19 may lead to higher credit card defaults over time, which could have an adverse effect on our profitability.
Failure to establish, maintain, protect, and enforce our intellectual property and proprietary rights or prevent third parties from making unauthorized use of our technology or our brand could harm our competitive position or require us to incur significant expenses to enforce our rights.
Our trademarks, such as Bond & Co., EveryYay, Good 2 Go, Good Lovin’, Harmony, Imagitarium, Leaps & Bounds, Pals Rewards, Petco, Petco Love, PetCoach, PupBox, Reddy, Ruff & Mews, So Phresh, Vetco, Well & Good, WholeHearted, You & Me, and Youly are valuable assets that support our brand and consumers’ perception of our products. We rely on trademark, copyright, trade secret, patent, and other intellectual property laws, as well as nondisclosure and confidentiality agreements and other methods, to protect our trademarks, trade names, proprietary information, technologies, and processes. We might not be able to obtain broad protection in the United States for all of our intellectual property. The protection of our intellectual property rights may require the expenditure of significant financial, managerial, and operational resources. Moreover, the steps we take to protect our intellectual property may not adequately protect our rights or prevent third parties from infringing or misappropriating our proprietary rights, and we may be unable to broadly enforce all of our trademarks. Any of our patents, trademarks, or other intellectual property rights may be challenged by others or invalidated through administrative process or litigation. Our patent and trademark applications may never be granted. Additionally, the process of obtaining patent protection is expensive and time-consuming, and we may be unable to prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. Even if issued, there can be no assurance that these patents will adequately protect our intellectual property, as the legal standards relating to the validity, enforceability, and scope of protection of patent and other intellectual property rights are uncertain. We also cannot be certain that others will not independently develop or otherwise acquire equivalent or superior technology or intellectual property rights. Further, our nondisclosure agreements and confidentiality agreements may not effectively prevent disclosure of our proprietary information, technologies, and processes and may not provide an adequate remedy in the event of unauthorized disclosure of such information, which could harm our competitive position. In addition, effective intellectual property protection may be unavailable or limited for some of our trademarks and patents in some foreign countries. We might be required to expend significant resources to monitor and protect our intellectual property rights. For example, we may need to engage in litigation or similar activities to enforce our intellectual property rights, to protect our trade secrets, or to determine the validity and scope of proprietary rights of others. However, we may be unable to discover or determine the extent of any infringement, misappropriation, or other violation of our intellectual property rights and other proprietary rights. Despite our efforts, we may be unable to prevent third parties from infringing upon, misappropriating, or otherwise violating our intellectual property rights and other proprietary rights. Any such litigation, whether or not resolved in our favor, could require us to expend significant resources and divert the efforts and attention of our management and other personnel from our business operations. If we fail to protect our intellectual property, our business, financial condition, and results of operations may be materially adversely affected.
Risks Related to Our Class A Common Stock
We are a holding company with nominal net worth and will depend on dividends and distributions from our subsidiaries to pay any dividends.
Petco Health and Wellness Company, Inc. and certain of our subsidiaries are holding companies with nominal net worth. We do not have any material assets or conduct any business operations other than our investments in our subsidiaries. Our business operations are conducted primarily out of our indirect operating subsidiary, Petco Animal Supplies Stores, Inc. and its subsidiaries. As a result, in addition to the restrictions on payment of dividends that apply under the terms of our existing indebtedness, our ability to pay dividends, if any, will be dependent upon cash dividends and distributions or other transfers from our subsidiaries. Payments to us by our subsidiaries will be contingent upon their respective earnings and subject to any limitations on the ability of such entities to make payments or other distributions to us.
General Risk Factors
An active, liquid trading market for our Class A common stock may not be sustained, which may limit your ability to sell your shares.
Prior to our initial public offering in January 2021, there was no public market for our Class A common stock. Although our Class A common stock is now listed on Nasdaq under the symbol “WOOF,” an active trading market for our shares may not be sustained. A public trading market having the desirable characteristics of depth, liquidity, and orderliness depends upon the existence of willing buyers and sellers at any given time, and its existence is dependent upon the individual decisions of buyers and sellers over which neither we nor any market maker has control. The failure of an active and liquid trading market to continue would likely have a material adverse effect on the value of our Class A common stock. The market price of our Class A common stock may decline. An inactive market may also impair our ability to raise capital to continue to fund operations by selling shares and may impair our ability to acquire other companies or technologies by using our shares as consideration.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
None.The following table provides information about purchases of the Company’s Class A common stock by the Company during the first quarter of 2022:
|
|
|
|
|
|
|
|
|
|
|
| |||||||||
|
| Total Number of Shares Purchased(1) |
| Average Price Paid Per Share |
| Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs |
|
| Approximate Dollar Value of Shares that May Yet be Purchased Under the Plans or Programs |
| ||||||||||
|
|
|
|
|
|
| ||||||||||||||
Period |
|
|
|
|
|
| ||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| |||||||||
January 30, 2022 to February 28, 2022 |
| — |
|
| — |
| — |
|
| — |
| |||||||||
March 1, 2022 to March 31, 2022 |
| 50,461 |
| $ | 19.93 |
| — |
|
| — |
| |||||||||
April 1, 2022 to April 30, 2022 |
| — |
|
| — |
| — |
|
| — |
| |||||||||
Total |
| 50,461 |
| $ | 19.93 |
| — |
|
| — |
|
(1) | Represents shares of the Company’s Class A common stock withheld from an employee upon the vesting of restricted stock to satisfy related tax withholding obligations. |
Item 3. Defaults Upon Senior Securities.
None.
Item 4. Mine Safety Disclosures.
Not applicable.
Item 5. Other Information.
None.
Item 6. Exhibits.
The following is a list of exhibits filed as part of this Quarterly Report on Form 10-Q:
Exhibit Number |
| Description |
|
|
|
| ||
10.1†
| ||
10.2† | ||
10.3† | Employment Letter between Petco Animal Supplies Stores, Inc. and John Zavada dated August 21, 2016 | |
10.4† | ||
10.5† | ||
31.1 |
| |
|
|
|
31.2 |
| |
|
|
|
32.1* |
| |
|
|
|
32.2* |
| |
|
|
|
101.INS |
| Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document |
|
|
|
101.SCH |
| Inline XBRL Taxonomy Extension Schema Document |
|
|
|
101.CAL |
| Inline XBRL Taxonomy Extension Calculation Linkbase Document |
|
|
|
101.DEF |
| Inline XBRL Taxonomy Extension Definition Linkbase Document |
|
|
|
101.LAB |
| Inline XBRL Taxonomy Extension Label Linkbase Document |
|
|
|
101.PRE |
| Inline XBRL Taxonomy Extension Presentation Linkbase Document |
|
|
|
104 |
| Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |
|
|
|
* | Furnished herewith and not deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, |
† | Management contract or compensatory plan or arrangement. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrantregistrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.authorized.
|
| Petco Health and Wellness Company, Inc. | |
|
|
|
|
Date: June | By: |
| /s/ |
|
|
|
|
|
|
| Chief Financial (Principal Financial and Accounting Officer) |
|
|
|
|
|
3027